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ABSTRACT 
 
Role of Mitochondria in TNF-alpha Neurotoxicity in Stroke 
 
Danielle N. Doll 
 
TNF-alpha is known to exacerbate infarct volume in animal models and elevated levels of TNF-
alpha are correlated with worse outcomes in stroke patients.  However, the mechanism is not 
well understood.  TNF-alpha has been shown to be neurotoxic at high doses and after long 
exposure times which is not clinically relevant.  Thus, we show for the first time that TNF-alpha 
at clinically relevant concentrations seen in the serum of stroke patients rapidly and profoundly 
decreases mitochondrial function resulting in neuronal cell death through activation of caspase 8 
and cytochrome c release. A slight decrease in mitochondrial function is detrimental to neurons 
due to their high energy demand.  Since TNF-alpha is known to be increased during ischemia 
and correlated with negative outcomes, it is important to understand the neurotoxic mechanism 
of TNF-alpha to develop potential therapeutic targets for stroke.  Moreover, TNF-alpha is 
increased during infections, and 30-40% of strokes occur during an active infection.  We show 
that having a stroke during an active bacterial infection mimic results in an increased infarct 
volume, worsened neurological deficits, and prolonged sickness behavior.  TNF-alpha’s rapid 
and profound effect on mitochondrial function may be one mechanism by which stroke severity 
is exacerbated, neurological deficits are worsened, and recovery delayed.  Thus, enhancing 
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1.1. Introduction on Stroke 
Approximately 800,000 Americans suffer from a stroke each year, and the American Heart 
Association predicts a 5.1 percent increase in stroke cases for Americans between 45 and 64 
years of age by 2030.  More than 137,000 people die from a stroke each year resulting in stroke 
being the fifth leading cause of death and leading cause of disability in the United States 
(American Heart Association, 2012).  Ischemic strokes which result from an interruption of 
blood flow to the brain due to a clot,  account for 87 percent of all stroke cases (American Heart 
Association, 2012).  Although ischemic stroke is a devastating problem in the United States and 
worldwide, the only FDA approved treatment is tissue plasminogen activator (tPA), which is a 
thrombolytic to break up the clot.  Unfortunately, less than 5 percent of patients receive tPA due 
to its limited time window of 4.5 hours; thus, most patients only receive supportive care 
(Fonarow et al., 2011). 
 
An occlusion of a cerebral artery causes deprivation of oxygen, glucose, and lipids resulting in 
necrotic brain tissue.  Breakdown of the blood-brain barrier and activation of inflammatory cells 
in the brain and in the periphery result in inflammation in the necrotic tissue (Davies et al., 1999; 
Zheng and Yenari, 2004).  Inflammatory mechanisms both in the periphery and in the central 
nervous system (CNS) are important in promoting brain inflammation by producing 
inflammatory mediators such as cytokines and clearing away dead tissue after cerebral ischemia 
(Danton and Dietrich, 2003).  Cytokines are key players in the inflammatory mechanism and 
contribute to the progression of ischemic damage (Liu et al., 1994).  The discovery of 
biomarkers and novel therapeutics for stroke has been the focus of extensive research recently; 
thus, understanding the roles of pro-inflammatory and anti-inflammatory cytokines that are 
produced during stroke will help us further understand how inflammation contributes to the 
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progression of ischemic damage and provide potential targets for novel therapeutics and 
biomarkers for prognosis of stroke.   
 
1.2. Stroke, Aging, and Immune System 
It was once thought that the brain was an immune-privileged organ and did not produce an 
inflammatory response to ischemic brain injury (Arvin et al., 1996).  However, it is now well 
established that cells in the brain produce and secrete cytokines, chemokines and adhesion 
molecules enabling the brain to mount a central and peripheral inflammatory response to 
ischemia (Liu et al., 1994; Ferrarese et al., 1999). Both central and peripheral inflammation are 
key contributors to the pathophysiology of stroke (Dirnagl et al., 1999; Wang et al., 2007a).   
There is increasing evidence that peripheral inflammation not only plays a role in the pathology 
of stroke but impacts stroke etiology by increasing susceptibility (Emsley and Hopkins, 2008).  
Risk factors such as atherosclerosis, obesity, diabetes, and hypertension are all associated with 
an increased peripheral inflammatory profile, and the majority of stroke patients have at least 
one of these risk factors (Hankey, 2006).  Many of these factors could participate in regulating 
interactions between the central and peripheral immune systems; those classically identified as 
immune response mediators and those traditionally unassociated.  A further understanding of the 
interaction between the immune and nervous system is important to determine the contribution 
of mal-adaptive immune responses as a causative factor resulting in poor functional outcome.   
 
Stroke most commonly occurs when an atherosclerotic plaque ruptures resulting in 
thromboembolism.  The initiation and progression of plaques are driven by inflammatory cells 
and mediators such as cytokines and chemokines (Hansson and Libby, 2006).  Dysfunctional 
endothelial cells of the vascular wall at the site of the atherosclerotic lesion express adhesion 
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molecules such as VCAM-1 and ICAM-1 that recruit macrophages and T cells (Cybulsky et al., 
2001).  These immune cells produce cytokines and chemokines along with vasoactive molecules 
that activates immune cells and smooth muscle cell proliferation resulting in the progression of 
the atherosclerotic lesion (McColl et al., 2009).  The continuous recruitment of immune cells and 
activation results in the formation of a mature plaque, and activated macrophages and T cells are 
significant part of the plaque (Zhou et al., 2000).  These activated immune cells secrete matrix 
metalloproteinases (MMPs) which are collagen-degrading proteases that destabilize the plaque 
and results in the rupture of the plaque causing ischemia (Johnson et al., 2005).  It is clear that 
inflammation is an essential contributor to the development and progression of atherosclerosis, 
and numerous pre-clinical studies show that animal models deficient in adhesion molecules, 
inflammatory mediators, and T cells attenuate the progression of plaque formation and the 
instability of the plaque (Boring et al., 1998; Dong et al., 2000; Zhou et al., 2000; Chi et al., 
2004).  Clinical studies using positron emission tomography (PET) have shown patients 
presenting with transient ischemic attack have high 18F-fluoreodeoxyglucose (FDG) signal in 
atherosclerotic plaques (Rudd et al., 2002; Davies et al., 2005).  FDG is taken up by 
macrophages and indicates the degree of macrophage activation, which further supports 
inflammation causing plaque instability (Warburton and Gillard, 2006).   
 
Increased atherosclerotic burden is a hallmark of obesity and diabetes, and these co-morbid 
diseases cause endothelial dysfunction through insulin resistance and inflammation (Hunt and 
Jurd, 1997).  Thus, risk factors such as obesity and diabetes increase stroke susceptibility 
through pro-atherogenic effects.  Furthermore, clinical studies have linked peripheral bacterial 
infections and increased stroke susceptibility during the first 3 days after infection (Grau et al., 
1998; Smeeth et al., 2004).  Infection is known to increase vascular disease, along with 
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increasing inflammatory mediators such as cytokines to clear the infection, which can promote 
the formation of plaques and increase destabilization of the plaque (Li et al., 2002; Michelsen et 
al., 2004).  Along with pro-atherogenic effects of infection, infection promotes a 
hypercoagulable state (Vila et al., 2000b).   Interleukin (IL)-6 and tumor necrosis factor-α (TNF-
α) are cytokines increased during the inflammatory response to infection that activate the tissue 
factor-mediated extrinsic pathway of coagulation, and clinical studies have observed in stroke 
patients with infections, increased platelet activation and decreased concentrations of anti-
coagulatory molecules such anti-thrombin, activated protein C, and free protein S (van der Poll 
et al., 1990; van der Poll et al., 1994)  Pre-clinical studies confirm these findings and 
demonstrate that systemic administration of pro-inflammatory cytokines mimic characteristics of 
infection. Obese animal models and animal models with other co-morbid diseases such as 
diabetic mice and spontaneously hypertensive rats exhibit larger infarcts and more severe 
neurological deficits (McGill et al., 2005; Terao et al., 2008).  These pre-clinical and clinical 
studies support the significance of peripheral inflammation and its impact on stroke and 
demonstrate how the interaction between the immune system and the brain can affect 
neurological dysfunction after an ischemic insult.   
 
Not only does acute and chronic inflammation preceding stroke increase susceptibility to stroke 
and increase brain damage after stroke, but stroke itself initiates a local inflammatory response 
in the brain and peripheral inflammation that can amplify this central inflammatory reaction.  
Interruption of cerebral blood flow results in the deprivation of oxygen, glucose, and other 
essential nutrients to the brain and leads to a complex, multifaceted cascade of inflammatory 
events.   
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It is evident that stroke is a vascular disease that results in neurological deficits after an ischemic 
insult, and it is not surprising that the prevalence of stroke increases with age because aging 
affects the vasculature and the immune system.  Capillary networks and density decrease during 
aging in the cortex of adult humans and animals (Brown et al., 2007b; Brown and Thore, 2011).  
Chronic inflammation and acute infection contribute to capillary disruption and cell loss 
resulting in a leaky BBB, and aged rodents exhibit increased BBB disruption along with reduced 
neurogenesis after stroke (Darsalia et al., 2005; DiNapoli et al., 2008; Ingraham et al., 2008).  In 
addition, age-associated immune system dysfunction increases incidence of acute infections, and 
co-morbid factors characterized by inflammation such as diabetes and atherosclerosis, and as 
discussed above, these co-morbid factors greatly increase susceptibility to stroke and worsen 
outcome after stroke (Castelo-Branco and Soveral, 2014).   
 
Aged individuals are in a chronic state of low grade inflammation referred to as inflamm-aging, 
and during inflamm-aging there is a shift in cytokines toward a pro-inflammatory state 
producing pro-inflammatory cytokines such as TNF-α and IL-1 (Bruunsgaard et al., 1999; 
Griffin, 2006).  The immune dysregulation theory supports the idea that during healthy aging 
anti-inflammatory mediators such as IL-10 inhibits the pro-inflammatory state; however, 
individuals’ systems that are challenged with acute infections, co-morbid factors, genetic 
predisposition, and environmental factors are unable to mount an anti-inflammatory response to 
the shift in a pro-inflammatory state resulting in an increase incidence of infections, co-morbid 
diseases, and stroke (Lio et al., 2004; Castelo-Branco and Soveral, 2014).   Thus, understanding 
the effect of age alone on stroke is difficult because it is likely that age is a surrogate for 
increased chronic inflammation associated with co-morbid diseases. This creates a pro-
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atherogenic and pro-coagulable state responsible for the increased incidence of stroke in the 
aged.   
 
1.3. Immune Response to Stroke 
The complex, multifaceted cascade of events that results from brain deprivation of oxygen, 
glucose, and other essential nutrients to the brain causes dysfunction of the neurovascular unit  
(del Zoppo, 2006).  Acutely after ischemia, microglia are activated due to the increase in 
extracellular ATP from the depolarization of neurons and glia, and activated microglia secrete 
cytokines and chemokines along with developing phagocytic properties (Melani et al., 2005).  
Within 4-6 hours after an ischemic insult, peripheral leukocytes migrate and adhere to vessel 
walls and infiltrate into the ischemic brain tissue producing deleterious inflammatory mediators 
(Wang et al., 2007a).  Numerous studies have shown that neutrophils are the first blood-derived 
cells from the periphery to infiltrate ischemic brain tissue, and when neutrophil infiltration is 
inhibited, infarct size is significantly decreased (Chopp et al., 1996; Hallenbeck, 1996; Yenari et 
al., 1998).  Reperfusion of the occluded vessel generates reactive oxygen species (ROS) 
resulting in further activation of immune and brain cells and oxidative stress, and these activated 
cells secrete cytokines, chemokines, MMPs, nitric oxide (NO), more ROS, and adhesion 
molecules that increase cell death and disruption of the blood-brain barrier (BBB) (Coyle and 
Puttfarcken, 1993; Melani et al., 2005).  Moreover, reperfusion and disruption of the BBB leads 
to further leukocyte infiltration into the brain amplifying the inflammatory response and 
enhancing damage.  The peripheral and central inflammatory response after ischemia leads to an 
increase in neuronal death, infarct size, and severity of stroke.   
 
8  
Adhesion molecules are essential for leukocytes to infiltrate into the brain after stroke, and 
notably ICAM-1 and VCAM-1, the same adhesion molecules that recruit immune cells to 
atherosclerotic lesions, mediate the interaction between leukocytes and the vascular endothelium 
(DeGraba, 1998).   Furthermore, both ICAM-1 and VCAM-1 expression increases after 
stimulation by cytokines such as TNF-α and IL-1 which are increased after stroke and in obese, 
diabetic, and atherosclerotic patients (Wang et al., 2007a).  An experimental stroke study in 
diabetic rats showed higher expression of ICAM-1 in diabetic rats after stroke compared to non-
diabetic rats, and this increase in adhesion molecules due to co-morbid diseases and infection 
could contribute to the exacerbation of stroke and increase susceptibility to stroke (Ding et al., 
2005).  Moreover, using ICAM-1 deficient mice and inhibiting ICAM-1 and VCAM-1in 
experimental stroke studies result in smaller infarct sizes, and clinically increased plasma and 
cerebral spinal fluid levels of ICAM-1 and VCAM-1 are observed in stroke patients and 
correlated with stroke severity (Connolly et al., 1996; Kitagawa et al., 1998; Selakovic et al., 
2003; Ehrensperger et al., 2005).  Thus, peripheral inflammation due to infection or other co-
morbid factors may increase stroke severity and stroke susceptibility by increasing adhesion 
molecules and other inflammatory mediators that produce an environment that enhances 
leukocyte activation and adhesion.   
 
Furthermore, brain and immune cells produce reactive oxygen species (ROS), and restoration of 
blood flow in the occluded vessel generates additional ROS (Coyle and Puttfarcken, 1993).  
ROS activate endothelial cells and cause oxidative stress (Melani et al., 2005; Schock et al., 
2007).  Oxidative stress and the induction of the inflammatory cascade leads to the breakdown 
of the blood-brain barrier allowing activated blood-borne immune cells such as neutrophils and 
T-cells to infiltrate and accumulate in the ischemic brain tissue (Melani et al., 2005).  Along with 
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the accumulation of activated immune cells from the periphery, microglia in the brain become 
activated after cerebral ischemia due to the increase in extracellular ATP from the depolarization 
of neurons and glia and the release through damaged plasma membranes of dying cells (Melani 
et al., 2005).  Activated microglia secrete pro-inflammatory mediators such as cytokines and 
develop phagocytic and major histocompatibility complex (MHC) class II-restricted antigen 
presenting characteristics (Davalos et al., 2005).  Microglia activation can be beneficial by 
producing growth factors such as brain-derived neurotrophic factor and clearing away dead 
tissue and debris after ischemia; however, the release of pro-inflammatory cytokines such as 
tumor necrosis factor-α (TNF-α) and production of reactive oxygen species and nitric oxide after 
microglia activation is detrimental (Cardenas et al., 2002; Tang et al., 2007).  ATP is an early 
danger signal increasing inflammation, but as cells die, molecular signals called danger 
associated molecular pattern molecules (DAMPs) are generated and activate pattern recognition 
receptors such as toll like receptors (TLRs) (Marsh et al., 2009).  These pattern recognition 
receptors are found on endothelial cells and microglia in the brain along with infiltrating 
leukocytes from the periphery, and activation of pattern recognition receptors increases 
cytokines (Marsh et al., 2009).  Moreover as neurons begin to die after ischemia, cell-cell 
interactions with microglia are lost and further increases inflammatory signaling (Matsumoto et 
al., 2007).  Thus acutely after ischemia, hypoxia and oxidative stress induces synthesis of 
nuclear factor κB (NF-κB), hypoxia inducible factor 1 and many other transcription factors that 
increase the expression of pro-inflammatory and anti-inflammatory cytokines (Baeuerle and 
Henkel, 1994).  As cells die and brain tissue is damaged, molecular danger signals further 
potentiate the inflammatory response by activating more microglia and infiltrating leukocytes in 
a feed-forward response producing more deleterious pro-inflammatory cytokines.  This increase 
in expression of cytokines further increases the expression of adhesion molecules on endothelial 
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cells that result in additional recruitment of leukocytes from the periphery (Bargatze et al., 
1994).  These inflammatory changes after ischemia lead to an increase in neuronal cell death 
resulting in a larger infract volume and worse outcome.  Inflammation is a key player in brain 
damage during cerebral ischemia; however, inflammation aiding in repair and recovery after 
cerebral ischemia can be beneficial.  Thus, further mechanistic understanding of how 
inflammation contributes to injury or repair after ischemia is important for discovering potential 
therapeutic targets for stroke and for using inflammatory mediators such as cytokines as 
biomarkers for prognosis.   
 
1.4. Mitochondria 
The brain represents only 2% of the body mass, but consumes >20% of O2 and glucose (Mink et 
al., 1981); the result of the high energy demand of neurons to maintain ion gradients (Attwell 
and Laughlin, 2001; Howarth et al., 2010; Harris and Attwell, 2012) and the almost exclusive 
use of mitochondrial oxidative phosphorylation for the production of ATP (Mergenthaler et al., 
2013). As such, even transient reductions in O2 or glucose put neurons at risk of dysfunction and 
death.  
 
During aging (Harman, 1972; Navarro et al., 2002), brain mitochondrial function is 
compromised, expressed as a reduction in oxidative phosphorylation (OxPhos), transport of 
mitochondria from soma to energy demanding synapses and excessive mitochondrial fission 
(Chaturvedi and Flint Beal, 2013). Thus normal aging sets the stage for limited mitochondrial 
response to ischemia. These mitochondrial defects could be responsible for the increase in the 
prevalence of stroke, increase in severity of infarcts and the limited recovery from stroke with 
advancing age.  
11  
With age, the brain experiences a reduced capacity to take up and utilize glucose as an energy 
source (Mink et al., 1981). This reduction in glucose utilization in the face of persistent energy 
demand means that the brain must tap into other sources of energy to supply its basic functions 
and to respond to ischemic events. In the absence of glucose, brain mitochondria use ketone 
bodies derived from endogenous sources or dietary lipids through β-oxidation to supply carbon 
fragments for OxPhos (Cahill, 2006). Inasmuch normal aging compromises mitochondrial 
structure, function and movement, the possibility is strong that progressive mitochondrial defects 
contribute to the age-related increase in stroke prevalence, severity and lack of recovery.   
 
Several neurological diseases such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s 
disease have a common pathological finding of neuroinflammation (Di Filippo et al., 2010).  
Moreover, it is well accepted during the pathogenesis of both inflammatory and 
neurodegenerative CNS disorders mitochondria are crucial players.  Because neurons are in high 
energy demand, and a slight decline in ATP production results in increased susceptibility to 
death leads to the hypothesis that mitochondrial dysfunction may be the link between 
neuroinflammation and neuronal degeneration.     Indeed, mitochondria can be the switch for the 
initiation of apoptosis through the opening of mitochondrial permeability transition pores 
(mtPTP) resulting in the dissipation of the mitochondrial inner membrane potential.  This 
dissipation of mitochondrial inner membrane potential causes the release of several molecules 
that activate caspases leading to apoptosis.  Several cytokines, including TNF-α, are known to 
affect mitochondrial function in non-neuronal cells; however, the cytokine-induced neuronal 
mitochondrial dysfunction still remains controversial.  Although it is believed that an acute 
neuroinflammation may be beneficial to the CNS through preconditioning to prevent further 
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damage to the neurons, chronic inflammation may represent a self-perpetuating detrimental 
response after an initial insult such as stroke.   
 
Further, the extent to which factors known to increase risk of stroke do so by decreasing 
mitochondrial function is a challenge to the field of stroke research. Dysregulated inflammation 
is associated with many of the risk factors associated with stroke such as hypertension, diabetes 
and obesity (Smith et al., 2013). An elevated systemic inflammatory profile is associated with 
atherosclerosis, hypertension, diabetes, obesity, and peripheral infection.  Thus far, studies have 
provided evidence that the release of oxidants, proteolytic enzymes and inflammatory cytokines 
alter blood brain barrier (BBB) permeability.  The BBB excludes the majority of bacteria; 
however, similar to ischemia and reperfusion, inflammation induced by bacteria alters BBB 
permeability.  Thus, understanding the effect of inflammation on mitochondrial function is 
important for increasing our understanding of how inflammation post-stroke can increase 
neurons susceptibility to death resulting in increased infarct size and poor outcome, and how 
inflammation plays a role in increasing the susceptibility to stroke.  Finally, methods of 
enhancing mitochondrial functions as a therapeutic target to prevent, treat and recover from 
stroke have not yet been explored.   
   
1.5. Cytokine Changes Following Stroke  
Cytokines are soluble glycoproteins that are produced by cells in the brain in response to 
damaged tissue after ischemia and are responsible for regulating the innate and adaptive immune 
response (Ferrarese et al., 1999).  Microglia, astrocytes, endothelial cells, and neurons in the 
brain are able to secrete pro-inflammatory and anti-inflammatory cytokines (Ferrarese et al., 
1999).  An increase in production of pro-inflammatory cytokines and a decrease in production of 
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anti-inflammatory cytokines is correlated with a larger infarct size in animal models and a worse 
clinical outcome (Vila et al., 2003).   TNF-α, interleukin (IL)-1β, IL-6, and IL-10 are 
inflammatory cytokines that have been found to be related to ischemic stroke and have been 
implicated as therapeutic targets and biomarkers for prognosis.  The inflammatory response to 
ischemia changes with time, and knowing the timing of when these cytokines are increased or 
decreased and how these cytokines affect infarct volume is important in understanding how 
cytokines can be utilized clinically.  TNF-α and IL-1β are well characterized in experimental 
stroke studies and human subjects.  However, little is known about the temporal profile of IL-6 
and IL-10, and fewer experimental stroke investigations have studied IL-6.   
 
A. TNF-α 
Tumor necrosis factor-alpha (TNF-α) precursor is membrane bound and cleaved by TNF-α 
converting enzyme (TACE) to release the soluble form that can bind to TNFR1 or TNFR2 (Liu 
et al., 1996).  Most cells in the brain express TNFR1, and TNFR1 has an intracellular death 
domain (DD) with which adaptor proteins such as TNFR-associated DD protein (TRADD) 
interacts, and the interaction of TRADD with the intracellular DD of TNFR1 elicits signaling for 
cell death or cell survival by recruiting other adaptor proteins (Liu et al., 1996; Gourin and 
Shackford, 1997; Chan et al., 2000).  The recruitment of adaptor proteins such as caspase-8 and 
FAS-associating protein with a death domain (FADD) result in apoptosis, and recruitment of 
TNF-receptor associating factor 2 (TRAF2) and receptor-interacting protein (RIP) activate NF-
κB resulting in activation of genes for anti-inflammatory, anti-apoptotic proteins along with pro-
inflammatory, apoptotic, and cytotoxic proteins (Gourin and Shackford, 1997).  Therefore, the 
structure of the TNF-signaling complex enables TNF-α to induce inflammation and cell death 
after stroke or induce tolerance to ischemia.  
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Experimental Stroke Studies 
Consequently in experimental stroke studies, it is not surprising that TNF-α has been shown to 
exacerbate infarct size and be neuroprotective.  In a mouse distal permanent middle cerebral 
artery occlusion (pMCAO) electrocoagulation ischemic model, intracisternal injection of TNF-α 
48 hours before occlusion decreases infarct volume (Nawashiro et al., 1997c).  Furthermore, 
using the same ischemia model TNF-α, TNFR1, and TNFR2 knock-out mice show larger infarct 
size compared to control mice suggesting that TNF-α is neuroprotective (Lambertsen et al., 
2009).  However, multiple approaches suggest that TNF-α is neurotoxic in stroke.  I.p. or i.v. 
injection of TNF-α binding protein immediately after occlusion and topical administration of 
TNF-α binding protein immediately and 1 hour after occlusion in the distal pMCAO 
electrocoagulation ischemic model causes a dose-dependent decrease in infarct volume at 1 
hour, 24 hours, and 2 weeks (Nawashiro et al., 1997a, b).  Also, in the one hour distal transient 
middle cerebral artery occlusion (tMCAO) filament ischemia mouse model, i.c.v. injection of 
anti-TNF antibody decreases infarct size (Yang et al., 1999).  In the rat ischemia model using the 
distal tMCAO and distal pMCAO where the vessel is occluded and cut, treating with TNF-α 24 
hours before occlusion is neurotoxic and increases infarct volume (Barone et al., 1997).  Also, in 
the distal pMCAO thromboembolic model, inhibiting TACE decreases infarct volume.  In 
agreement with the mouse model, administrating anti-TNF antibody and TNF-α binding protein 
in the rat ischemia model decreases infarct volume (Dawson et al., 1996; Lavine et al., 1998).  
The neurotoxic versus neuroprotective action of TNF-α is most likely due to signaling through 
nuclear factor κB producing both pro-inflammatory and anti-inflammatory mediators and the 




Time Course in Experimental Stroke Studies 
After stroke onset, TNF-α mRNA expression is induced within thirty minutes after both tMCAO 
and pMCAO in mice and rats, and TNF-α protein expression is seen within 1 hour in the cortex 
and striatum after tMCAO in spontaneously hypertensive rats (Liu et al., 1994).  Levels of TNF-
α mRNA and protein peak between 12 and 24 hours in both mice and rats and remain elevated 
up to 10 days in mice and 6 days in rats (Buttini et al., 1996; Gregersen et al., 2000).  The timing 
of the expression of TNF-α after ischemia is found to be comparable among different mouse 
strains after pMCAO, but the level of expression is different (Lambertsen et al., 2002).  Cells 
producing TNF-α are found at 12 and 24 hours after stroke in the penumbra of all mouse strains 
(Lambertsen et al., 2002).  Interpretation of the time course of TNF-α is complicated in animal 
models because of the use of different strains of mice and rats, different methods for measuring 
levels of TNF-α, and the time after stroke when levels are measured.   
 
Time Course in Human Studies 
In postmortem brain tissue studies, TNF-α positive cells are observed in all ischemic brains of 
severe patients 3 days post-stroke and are present up to 15 months post-stroke, and the majority 
of TNF-α positive cells are microglia and macrophages (Tarkowski et al., 1997; Dziewulska and 
Mossakowski, 2003).  TNF-α positive neurons peak between 2 and 3 days post-stroke, TNF-α 
positive infiltrating immune cells from the periphery peak at day 3, and TNF-α positive 
astrocytes peak from 15 hours to 14 days (Sairanen et al., 2001).  Furthermore, TNF-α levels 
have been measured in CSF at 0, 3, 7, 9, 21, 26 days and 3 months after stroke, and TNF-α 
levels are only increased in stroke patients with white matter damage compared to normal 
controls at 3 months post-stroke (Tarkowski et al., 1997).  However, other studies have shown 
that TNF-α levels are increased within 24 hours in the CSF (Vila et al., 2000a; Zaremba and 
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Losy, 2001).  Studies assessing TNF-α in serum of stroke patients have not been conclusive. A 
few studies found that serum TNF-α levels are not increased at admission or any time between 
12 hours and 10 days after stroke (Fassbender et al., 1994; Montaner et al., 2003; Ormstad et al., 
2011b).  In contrast, other studies have shown that TNF-α is increased in the serum of stroke 
patients compared to controls within 6 hours  and stay elevated for 10 days post-stroke (Zaremba 
and Losy, 2001; Intiso et al., 2003).  Moreover, studies measuring TNF-α in plasma observed a 
significant increase of TNF-α in stroke patients at admission and within 24 hours post-stroke 
(Vila et al., 2000a; Castellanos et al., 2002).  The time after stroke when levels of TNF-α are 
measured is critical and a contributing factor to the difference in results among and between 
animal and human studies.  Additionally, the severity of stroke may be a key factor in the timing 
and magnitude of the increase in TNF-α.  
 
B. IL1-β 
IL1-β mRNA and protein is constitutively expressed in the brain at low levels and is regulated 
by transcription, translation, cleavage and cellular release.  IL1-β is synthesized as a large 
precursor protein and is biologically inactive until it is cleaved by caspase-1 and secreted 
(Thornberry et al., 1992).  Once it is biologically active, it binds to type 1 IL-1 receptor (IL-1R1) 
which associates with IL-1-receptor accessory protein (IL-1RAcP) that initiates intracellular 
signaling (Korherr et al., 1997).  IL1-β can also bind to IL-1R2, but IL-1R2 does not initiate 
downstream signaling because IL-1R2 does not have an intracellular-signaling domain 
(Thornberry et al., 1992; Korherr et al., 1997).  Furthermore, IL-1R1 and IL-1R2 can exist in 
soluble forms when they are shed from cell membranes (Thornberry et al., 1992; Korherr et al., 
1997; Allan et al., 2005).  IL-1R2 and the soluble forms of both receptors act as decoy receptors 
that prevent a ligand from initiating signaling pathways (Allan et al., 2005).  During acute 
17  
ischemia, there is an increase in ATP which promotes the cleavage and cellular release of IL1-β 
(Thornberry et al., 1992).  An increase in IL1-β can cause an increase in calcium entry through 
NMDA-receptor ion channels resulting in neuronal cell death (Viviani et al., 2003).  
Furthermore, IL1-β can potentiate inflammation by activating microglia, and IL1-β increases 
leukocyte infiltration by increasing the expression of adhesion molecules on endothelial cells 
and causing breakdown of the blood brain barrier contributing to an increased infarct size and 
poor clinical outcome (Bernardes-Silva et al., 2001; Konsman et al., 2004; Mazzotta et al., 
2004).  
 
Experimental Stroke Studies 
Numerous studies have shown IL1-β to be neurotoxic in animal ischemia models.  In the mouse 
distal electrocoagulation pMCAO model, injecting an IL-1 receptor antagonist immediately and 
4 hours after stroke decreases infarct volume (Nawashiro et al., 1997b).  Moreover in the 
proximal tMCAO filament model, treating with caspase-1 inhibitors 15 minutes before and 
immediately after stroke decreased infarct volume, and using caspase-1 knock-out mice result in 
smaller infarct volume compared to control mice (Hara et al., 1997a; Hara et al., 1997b).  IL1-αβ 
knock-out mice also show smaller infarct volumes (Ohtaki et al., 2003).  Similarly, the rat 
proximal electrocoagulation and filament pMCAO model exhibit an increase in infarct size in 
animals treated with IL1-β 30 minutes before and after stroke and a smaller infarct size, 
improved neurological score, and decreased number of leukocytes in the ischemic tissue when 
treated with an IL-1 receptor antagonist at the time of occlusion along with injections at 4, 8, 12, 
and 18 hours after stroke (Garcia et al., 1995; Loddick and Rothwell, 1996; Relton et al., 1996).  
Proximal tMCAO filament models further shows IL1-β neurotoxicity, confirming what was seen 
in the rat pMCAO and mouse ischemia models.  Caspase-1 inhibitors decrease infarct volume in 
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the tMCAO filament model when injected 15 minutes before surgery and after reperfusion, and 
injecting IL1-β after reperfusion increases infarct size and brain edema (Yamasaki et al., 1995; 
Hara et al., 1997b).  IL-1β is a potent pro-inflammatory cytokine and has a role in activation of 
numerous inflammatory processes. Using different ischemia models and different treatments to 
enhance or inhibit IL-1β has resulted in the observation that IL-1β is constantly neurotoxic in 
experimental stroke models. 
 
Time Course in Experimental Stroke Studies 
IL1-β positive microglia cells are found in the cortex 6 to 24 hours after stroke and elevated IL1-
β mRNA levels are observed at 10 hours in the brain tissue in both the proximal pMCAO and 
proximal tMCAO filament mouse model (Hill et al., 1999; Clausen et al., 2008).  However, 
levels of IL1-β mRNA peak later at 18 hours in the pMCAO model compared to peak levels at 
10 hours in the tMCAO model.  In rat ischemia models, peak levels of IL1-β mRNA are seen at 
6 hours in the proximal tMCAO and distal pMCAO suture model (Wang et al., 1994; Berti et al., 
2002) and elevated levels are seen as early as 1 hour after stroke (Liu et al., 1993; Wang et al., 
1994).  Thus, both rat and mouse ischemia models show an early increase in expression of IL-1β 
with peak expression dependent on the occlusion model used.  Reperfusion allows for increased 
access of leukocytes to the brain which may contribute to levels of expression peaking earlier in 
the tMCAO model.     
 
Time Course in Human Studies 
IL1-β is elevated in the CSF of severe stroke patients with peak levels at 2-3 days post-stroke 
(Tarkowski et al., 1995, 1997).  However another study showed, IL1-β in CSF was elevated 
within 6 hours after stroke regardless of its severity (Beridze et al., 2011).  Two peripheral blood 
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studies found elevated levels of IL1-β in plasma and serum of stroke patients (Mazzotta et al., 
2004; Sotgiu et al., 2006).  However, all other studies showed no increase of IL1-β in serum or 
plasma (Fassbender et al., 1994; Tarkowski et al., 1995; Ormstad et al., 2011b).  IL-1β has a 
highly localized role at the site of inflammation, and this localized role may be why IL-1β is not 
seen in plasma or serum of stroke patients.  However, soluble IL-1 receptor decoys are elevated 
in plasma very early after stroke onset, which suggests an early attempt to regulate IL-1β 
supporting the important role IL-1β plays in stroke (Emsley et al., 2007).   
 
C. IL-6 
IL-6 is an inflammatory cytokine that binds to class I cytokine receptors (Erta et al., 2012).  
Class I cytokine receptors do not have intrinsic enzyme activity; thus, IL-6 signaling through its 
class I cytokine receptor requires recruitment of an additional receptor protein gp130 (Saito et 
al., 1992).  IL-6 signaling activates intracellular tyrosin-kinases such as Janus Kinase (JAK) 
which activates signal transducer and activator of transcription (STAT) family of transcription 
factors and RAS-RAF-MAPK pathways (Erta et al., 2012).  These transcription factors and 
pathways can increase astrogliosis and angiogenesis which are important for tissue remodeling 
and recovery after stroke (Tancredi et al., 2000; Hakkoum et al., 2007).  Furthermore, IL-6 can 
inhibit TNF-α, induce apoptosis in neutrophils, and recruit monocytes and T-cells causing the 
transition between innate and adaptive immune response (Marz et al., 1996).  However, IL-6 can 
be detrimental by increasing body temperature which has been shown to increase brain damage 





Experimental Stroke Studies 
Few studies have been completed that assess IL-6 and stroke.  IL-6 knock-out mice do not show 
a difference in infarct size compared to wild types mice in the proximal tMCAO filament model 
(Clark et al., 2000).  However, when body temperature of IL-6 knock-out mice is controlled to 
levels of wild type mice, IL-6 knock-out mice exhibit larger infarcts suggesting IL-6 is 
neuroprotective (Herrmann et al., 2003).  This finding is consistent with the proximal pMCAO 
electrocoagulation rat model in which IL-6 was injected 30 minutes before and 15 minutes after 
pMCAO and infarct size was reduced (Loddick et al., 1998).   
 
Time Course in Experimental Stroke Studies 
IL-6 is elevated as early as 3-3.5 hours post-stroke and peaks between 6 and 24 hours depending 
on the ischemia model.  In both mouse proximal pMCAO and tMCAO filament model, levels of 
IL-6 mRNA are elevated at 10 hours and peak expression is at 18 hours.  In rat proximal 
tMCAO models, elevated IL-6 mRNA and protein levels are seen 3-3.5 hours after stroke and 
peak expression of IL-6 protein at 12 and 24 hours (Wang et al., 1995; Suzuki et al., 1999).  
  
Time Course in Human Studies 
CSF IL-6 is elevated in stroke patients and increases within 24 hours and peaks 2-3 days after 
stroke (Tarkowski et al., 1995, 1997).  Vila et al. (2000a) and Beridze et al. (2011) found that 
CSF IL-6 levels are elevated but only in severe stroke patients.  Furthermore, IL-6 is elevated in 
serum and plasma during the first week after stroke in all published studies.  However, some 
studies show IL-6 levels peaking at 10 hours in serum while other studies show levels of IL-6 
peaking between 3 and 7 days after stroke (Fassbender et al., 1994; Perini et al., 2001; Waje-
Andreassen et al., 2005).  Thus, there is agreement that IL-6 is elevated in stroke patients during 
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the week after stroke onset.  However, the timing at which IL-6 levels peak appear to depend on 
stroke severity and stroke type.   
 
D. IL-10 
IL-10 is an anti-inflammatory cytokine that signals through the IL-10 receptor complex, 
composed of two chains of IL-10R1 and two chains of IL-10R2 (Krause et al., 2002).  The two 
chains of IL-10R1 bind IL-10 and IL-10R2 initiates signal transduction.  Jak1 is constitutively 
bound to IL-10R1 and Tyk2 is constitutively bound to IL-10R2, and when the IL-10 receptor 
complex is activated by IL-10, two tyrosine residues on the intracellular domain of IL-10R1 are 
phosphorylated by cross-phosphorylation and Jak1 and Tyk2 become activated (Kotenko et al., 
1996).  Stat3 interacts with these phosphorylated tyrosines to phosphorylate other Stat proteins 
that translocate to the nucleus to activate transcription of Stat3-responsive genes (Finbloom and 
Winestock, 1995).  IL-10 signaling blocks pro-inflammatory cytokine production, chemokine 
secretion, and inhibits antigen presentation by macrophages and microglia (Ooboshi et al., 
2005).  Furthermore, IL-10 can counteract the detrimental effects of TNF-α by inhibiting 
activation of signaling pathways induced by TNF-α (Liesz et al., 2009).  IL-10’s beneficial anti-
inflammatory effects are an attractive target for potential clinical applications in stroke.   
 
Experimental Stroke Studies 
Administration of IL-10 into the lateral ventricle 30 minutes and 3 hours after stroke in the 
pMCAO electrocoagulation rat model significantly decreases infarct size (Spera et al., 1998).  In 
the same model, infarct size is significantly decreased when IL-10 is administered 30 minutes 
post stroke for 3 hours systemically into the tail vein (Spera et al., 1998).  Furthermore, injecting 
adenoviral vectors encoding IL-10 into the lateral ventricle 60-90 minutes before photochemical 
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occlusion or bilateral carotid occlusion in rats decreases infarct size and infiltrating leukocytes 
(Ooboshi et al., 2005).  In a mouse transgenic model in which astrocytes, microglia, and 
endothelial brain cells overexpress IL-10, smaller infarcts are observed, and IL-10 deficient mice 
show larger infarcts after pMCAO (Grilli et al., 2000; de Bilbao et al., 2009).  Another study 
suggesting the beneficial role of IL-10 in stroke, found a subset of regulatory B-cells that secrets 
IL-10 can decrease infarct size and improve neurological score (Fillatreau et al., 2002; Mann et 
al., 2007; Ren et al., 2011).  Collectively, all experimental stroke studies suggest that IL-10 is 
neuroprotective through suppression of the inflammatory response after ischemia.   
 
Time Course in Experimental Stroke Studies  
IL-10 mRNA expression is increased in the ipsilateral cortex of the pMCAO mouse model at 6 
hours and peaks at 7 days, and  IL-10 receptor mRNA is upregulated after pMCAO (Li et al., 
2001; Perez-de Puig et al., 2013).  At 1, 4, and 7 days after pMCAO, IL-10 receptor positive 
cells are found in the subarachnoid space and on the surface of the infarcted cortex, and IL-10 
receptor positive astrocytes are found in the infarcted tissue at day 4 (Perez-de Puig et al., 2013).  
Furthermore in the rat ischemia model, IL-10 is decreased 12 hours after stroke but increases 
six-fold two days post-stroke (Li et al., 2001).  Few studies have examined the temporal profile 
of IL-10 in experimental stroke models, and these studies measured IL-10 mRNA expression in 
the brain not in the periphery.   
 
Time Course in Human Studies 
More studies have assessed the temporal profile of IL-10 in human subjects. Stroke patients 
show lower levels of IL-10 in plasma within 12 hours after stroke compared to controls, and 24 
hours after tPA treatment IL-10 levels are increased (Perini et al., 2001; Mazzotta et al., 2004).  
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Furthermore, levels of IL-10 are decreased within 24 hours of stroke and levels increase over 72 
hours post-stroke (Nayak et al., 2012).  Studies report a huge variability in the levels of IL-10, 
which is most likely due to the time the sample was taken and stroke severity.  Furthermore, the 
heterogeneity of co-morbidities among stroke patients could play a role in the variability in 
levels of IL-10 and other cytokines after stroke.   
 
1.6. Effects of Cytokines on Stroke Outcome 
The inflammatory response to ischemia plays an essential role in the pathophysiology of stroke, 
and using inflammatory markers such as the cytokines described above can be useful to predict 
outcome after stroke.  Increased mortality and functional disability occurs in stroke patients who 
show neurological symptoms that progress acutely after stroke onset.  The ischemic penumbra is 
the tissue that surrounds the infarct core and can survive or be transformed into necrotic tissue 
and become part of the infarcted tissue due to reduced blood flow and impaired neuronal 
function (Astrup et al., 1981).  The transformation of the penumbra to infarcted tissue results in 
worsening of neurological symptoms (del Zoppo et al., 2011).  Increased levels of IL-6 in both 
CSF and serum have been associated with worsening of neurological symptoms, increased 
infarct size and poor functional outcome (Tarkowski et al., 1997; Vila et al., 2000a; Beridze et 
al., 2011).  It is surprising that IL-6 is associated with poor functional outcome in humans since 
in experimental stroke studies IL-6 was found to be neuroprotective.  However, Ormstad et al. 
(2011b) found no correlation between IL-6 and infarct size, and Sotgiu et al. (2006) found an 
inverse correlation of IL-6 with infarct size and poor outcome.  IL-6 can cause the release of 
prostaglandin E2 in the brain, and prostaglandin E2 acts on the hypothalamus resulting in an 
increase in body temperature.  Numerous human and experimental stroke studies have shown 
that fever is correlated with increased infarct size and poor outcome; thus, the early increase in 
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IL-6 and prolonged elevation of IL-6 in the CSF and blood most likely correlates with increased 
risk of elevated temperature that increases inflammation and tissue damage after stroke.  
Moreover, there are conflicting findings when using TNF-α as an inflammatory mediator for 
predicting outcome and infarct size.  Increased levels of TNF-α in the serum and CSF of stroke 
patients is correlated with worsening of neurological symptoms, increased infarct size and poor 
outcome at 3 months in studies including severe strokes and patients with white matter damage 
(Tarkowski et al., 1995; Zaremba and Losy, 2001; Castellanos et al., 2002; Montaner et al., 
2003; Mazzotta et al., 2004).  However, in other studies TNF-α was not correlated with outcome 
or infarct size (Vila et al., 2000a; Intiso et al., 2003).  Although IL-1β was neurotoxic in all 
experimental ischemic animal studies, IL-1β was only found to be correlated with poor outcome 
in the plasma of patients in one study which is most likely due to the localized role of IL-1β and 
low levels of IL-1β in the blood or CSF (Mazzotta et al., 2004).  The anti-inflammatory effects 
of IL-10 play an important role in preventing neuronal death; thus, it is not surprising that low 
levels of IL-10 early after stroke onset is correlated with poor outcome and increased infarct size 
(Mazzotta et al., 2004).  However, a trend toward increased levels of IL-10 days after stroke and 
even at admission correlate with poor outcome and an increased risk for infection (Chamorro et 
al., 2006).  Increased IL-10 down regulates TNF-α and inhibits IFN-γ production which can be 
beneficial in the earlier phases of infarct progression after stroke; however, the increase in IL-10 
can induce peripheral immunosuppression resulting in post-stroke infection and infections are 
the leading cause of death in stroke patients (Zhang et al., 2010).   
 
The variability of the data on peripheral cytokines in human stroke is most likely due to the 
heterogeneity of stroke in humans.  Stroke severity, stroke location, age, co-morbidities, and 
systemic inflammation prior to stroke may be key factors contributing to the levels of peripheral 
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cytokines seen post-stroke.  Furthermore, proper control subjects are important for interpreting 
cytokine data.  In human stroke studies assessing IL-10, TNF-α, IL-1β, IL-6, and other 
inflammatory mediators, the majority of the studies had age-matched controls but some studies 
had healthy controls subjects while other studies had controls with co-morbidities such as 
hypertension or diabetes.  In addition, other studies compared cytokine levels based on stroke 
severity.   Thus, it is important to control for co-morbidities and risk factors to determine which 
and when cytokines are increased due to stroke.  Consequently, the use of only one 
inflammatory mediator to predict outcome or infarct size is not clinically useful due to the 
heterogeneity of the peripheral cytokine response.  Therefore, further understanding of when 
these cytokines are increased and how they interact with each other can help elucidate how these 
cytokines can be used clinically as biomarkers to help predict outcome.   
 
I assessed the effects of these 4 cytokines on neuronal mitochondrial function with the 
hypothesis that pro-inflammatory cytokines (TNF-α and IL-1β) would decrease mitochondrial 
function resulting in neurotoxicity and anti-inflammatory cytokines (IL-6 and IL-10) would 
increase mitochondrial function resulting in neuroprotection.  I found that exposure to 1000 
ng/ml IL-1β for 12 hours significantly decreased neuronal ATP production and maximal 

































Figure 1.1: ATP production and Maximal respiration after 12 hour exposure to IL-1β. * p < 0.05 
 
IL-6 (Figure 1.2) and IL-10 (Figure 1.3) both increased neuronal mitochondrial function after 6 
hours of exposure; however, TNF-α had the most profound dose-dependent effect on neuronal 
mitochondrial function; thus, we decided to further investigate the mechanism by which TNF-α 
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Figure 1.2: ATP production and Maximal respiration after 6 hour exposure to IL-6. * p < 0.05;  
** p < 0.01 
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Figure 1.3: ATP production and maximal respiration after 6 hour exposure to IL-10.  
 
1.7. Gaps in Knowledge 
Since cytokines play an essential role in stroke and have potential clinical utility, it is critical to 
understand how experimental and human studies contribute to our knowledge on how to 
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effectively use cytokines clinically and how experimental and human studies can be improved to 
increase the likelihood of clinically translatable results.  An important confounding factor in 
understanding the role of peripheral cytokines in human stroke is that experimental stroke 
studies observe the cytokine response to stroke in the brain not in the periphery.  Furthermore, in 
experimental stroke studies both permanent and transient MCAO models are invasive and could 
contribute to the cytokine response especially in stroke models that involves craniectomy.  
Transient MCAO mimics occlusion and reperfusion while pMCAO mimics just occlusion.  
Although reperfusion can attenuate infarction, it allows for increased infiltration of leukocytes 
into the brain, and the contribution of cytokines from peripheral leukocytes in affecting the 
progression of infarction and the difference in kinetics of leukocytes in the two ischemia models 
is not well studied. Thus, further understanding of how reperfusion can affect cytokine levels 
and their impact on outcome will be beneficial clinically in patients that receive tPA.  Although 
outlined above is the signaling mechanisms for TNF-α, few studies have assessed mechanisms 
of TNF-α or any other cytokines in stroke, and there is a substantial lack in understanding of 
how cytokines balance their neuroprotective and neurotoxic action after stroke. Understanding 
this balance is crucial for defining a therapeutic time window for using cytokines as biomarkers 
or therapeutic targets.   
 
Understanding the effects of different experimental stroke models on cytokine expression is 
important, but equally important is understanding how location of stroke, age, co-morbid 
diseases and environmental factors affect cytokine expression in human stroke studies.  Thus, 
using clinically relevant stroke models such as aged animals, animals with hypertension, 
diabetes, etc., and producing strokes in different locations will provide essential information on 
cytokine expression that can be more easily translated from the bench to the bedside.  
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Additionally, few human stroke studies assess the peripheral cytokine response before 4 hours 
after stroke which is a critical time in infarct progression, and early inflammatory events have 
been show to play a role in recovery from stroke.  Thus, understanding these early cytokines 
responses and their effects early post-stroke is critical in using cytokines as biomarkers for 
prognosis and therapeutic targets.  Designing clinical stroke studies to have power to do analysis 
on cytokine expression controlling for time, location, and co-morbidities and designing pre-
clinical stroke studies to assess cytokine expression in peripheral blood as well as brain will be 
critical for the use of cytokines as prognostic biomarkers for stroke.  
While prognostic biomarkers are important clinically, it is equally as important to find new 
therapeutic targets for stroke.  Currently there is only one FDA approved drug for stroke, tPA, 
that less than 5% percent of patients receive.  Thus, understanding the mechanism by which 
cytokines such as TNF-α exacerbate stroke damage and the expression of these cytokines pre 
and post-stroke is critical for the advancement of stroke research.  
  
 1.8. Summary 
It is clear that cytokines play an important role in the pathophysiology and etiology of stroke, 
and the loss in balance between pro-inflammatory and anti-inflammatory cytokines affects 
infarct size and functional outcome.  Thus, focusing on one cytokine only as a potential 
biomarker or a therapeutic target likely will not be advantageous in stroke.  Future work needs to 
elucidate the temporal profile of cytokines in the periphery in human and experimental stroke 
studies to determine which cells contribute to the elevation of cytokines in the brain and blood 
and to understand how they work in concert to provide neuroprotection or increase 
neurotoxicity.  The crosstalk between the immune system and the brain is still not well 
understood.  Using cytokines as biomarkers or therapeutic targets may be beneficial to 
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understand the post-ischemic immune response and its effects on outcome clinically and to 
modulate the post-ischemic immune response to limit tissue damage.  However, modulation of 
the immune response can also be detrimental after stroke; thus, it is imperative that further 
clinical and experimental studies be pursued to better understand the complex interaction 
between the immune system and the brain after stroke.  Moreover, understanding how having a 
stroke during an active infection or a pro-inflammatory state contributes to the long-term deficits 
post-stroke is essential for future treatment of stroke.  Numerous risk factors such as diabetes, 
hypertension, and atherosclerosis have been recognized to increase susceptibility to stroke; 
however, the epidemiology of ischemic stroke is not sufficiently explained by the prevalence of 
these cerebrovascular risk factors (Grau et al., 1995b).  In at least a third of ischemic stroke 
cases, the patients lack traditional risk factors and have no apparent cause.  The presence of 
systemic infection could be an important mediating risk factor.  Indeed, thirty to forty percent of 
strokes occur during or acutely after an infection (Grau et al., 1995b) suggest an association 
between systemic infection and stroke.  Recent studies have indicated that both Helicobacter 
pylori (H. pylori) (Wang et al., 2012) and human cytomegalovirus (HCMV) (Huang et al., 2012) 
infections are associated with increased risk for ischemic stroke.   Moreover, having a 
respiratory tract infection increases one’s risk for an atherothrombotic ischemic event for up to 3 
months (Zurru et al., 2009) and chronic bronchitis increases risk for stroke and transient 
ischemic attacks (TIA) (Grau et al., 2009).   Lastly, Grabska et al. (2011) conducted a 
retrospective chart review of 2066 ischemic stroke patients to assess the effect of pre-stroke and 
post-stroke infection on ischemic stroke severity and found that pre-stroke infection increased 
poor outcomes within the first 30 days but did not have effects at 90 days on modified Rankin 
scores.  Thus whether it is traditional stroke risk factors or infection that increases susceptibility 
to stroke, a key feature is an increased pro-inflammatory profile.  McColl et al. (2007) found that 
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the combination of a minor bacterial infection mimic, lipopolysaccharide (LPS) prior to a minor 
stroke exacerbates infarct volume in a mouse model.  Thus, experimental and epidemiological 
data strongly suggest that infection and/or inflammation play a role in stroke occurrence and 
severity.  However, to date, long-term outcomes of stroke during an active infection has not been 
studied.  
 
Thus, my dissertation will use post-stroke relevant concentrations of TNF-α and clinically 
relevant exposure times to understand 1) if TNF-α affects neuronal mitochondrial function and 
2) if TNF-α affects neuronal mitochondrial function, the mechanism by which it occurs. 
Additionally, my dissertation will focus on 3) if a bacterial infection mimic, lipopolysaccharide 
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Tumor necrosis factor alpha (TNF-α) is known to exacerbate ischemic brain injury; however, the 
mechanism is unknown.  Previous studies have evaluated the effects of TNF-α on neurons with 
long exposures to high doses of TNF-α, which is not pathophysiologically relevant.  We 
characterized the rapid effects of TNF-α on basal respiration, ATP production, and maximal 
respiration using pathophysiologically relevant, post-stroke concentrations of TNF-α.  We 
observed a reduction in mitochondrial function as early as 1.5 hours after exposure to low doses 
of TNF-α, followed by a decrease in cell viability in HT-22 cells and primary neurons.  
Subsequently, we used the HT-22 cell line to determine the mechanism by which TNF-α causes 
a rapid and profound reduction in mitochondrial function.  Pre-treating with TNF-R1 antibody, 
but not TNF-R2 antibody, ameliorated the neurotoxic effects of TNF-α indicating TNF-α exerts 
its neurotoxic effects through TNF-R1.  We observed an increase in caspase 8 activity and a 
decrease in mitochondrial membrane potential after exposure to TNF-α which resulted in a 
release of cytochrome c from the mitochondrial into the cytosol.  These novel findings indicate 
for the first time that an acute exposure to pathophysiologically relevant concentrations of TNF-











Inflammatory mechanisms play a crucial role in the pathophysiologic processes after the onset of 
ischemic stroke (Vila et al., 2000a).  Ischemic brain injury is complex, and intracellular 
signaling that regulates innate and adaptive immunity, inflammation, cell death, angiogenesis, 
and repair processes plays an important role in the initiation, progression, and resolution of 
ischemia.  Initiation of these critical intracellular regulators occurs through rapid cytokine 
signaling after ischemia, highlighting cytokines as key regulators of stroke damage (Hallenbeck, 
2002).   TNF-α is one of many pro-inflammatory cytokines associated with worsened clinical 
outcomes after stroke and exacerbations of infarct size in pre-clinical models (Nawashiro et al., 
1997c; Ormstad et al., 2011a).  However, our understanding of the pro-inflammatory effects of 
TNF-α is based primarily on studies of its peripheral actions.  
 
TNF-α mRNA increases within 1 hour in the ischemic injury core, and the expression of its 
immunoreactive protein increases within 2-6 hours after the onset of ischemia in pre-clinical 
models (Botchkina et al., 1997). TNF-α is increased in the serum of stroke patients between 6 
and 12 hours after symptom onset (Liu et al., 1994; Sotgiu et al., 2006).  TNF-α  signaling 
occurs through the TNF-α receptor (TNF-R), where ligand binding recruits adaptor proteins to a 
core signaling complex allowing for differences in signal transduction depending upon the 
stimulatory pattern (Wallach et al., 2002).   
 
The response to TNF-α is cell-type dependent.  In bovine and rat oligodendrocytes, TNF-α 
induces apoptosis, while in astrocytes, TNF-α enhances major histocompatibility complex 
(MHC) class II and intracellular adhesion molecule 1 (ICAM-1) expression (Chao et al., 1995).  
In primary septo-hippocampal cultures, exposure to 30 ng/ml of TNF-α caused significant 
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cytotoxicity but only with the addition of Actinomycin-D (Zhao et al., 2001).  When rat primary 
cortical neurons are exposed to 10 ng/ml of TNF-α for 24 hours, neurite retraction or formation 
of apoptotic bodies were not observed (Reimann-Philipp et al., 2001).  However, in PC12 cells, 
TNF-α was cytotoxic (Reimann-Philipp et al., 2001).  While these studies show neurotoxic 
effects of TNF-α, cultured embryonic rat hippocampal, septal, and cortical neurons are protected 
from glucose deprivation-induced injury and excitatory amino acid toxicity by exposure to TNF-
α (Cheng et al., 1994).  Furthermore, TNF-α can induce the expression of anti-apoptotic proteins 
B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) in hippocampal neurons 
(Tamatani et al., 1999).  These few studies used high concentrations and long periods of 
exposure to TNF-α. Also, there is a single study, of adipocytes that used high concentrations and 
4 day exposures to assess mitochondrial function (Chen et al., 2010). 
 
In the present study, we tested the hypothesis that acute exposure to TNF-α concentrations seen 
in serum of stroke patients (Lambertsen et al., 2012; Nayak et al., 2012) causes neuronal cell 
death through rapid mitochondrial dysfunction.  As such, we characterized the effect of acute 
exposure to low doses of TNF-α in a mouse hippocampal neuronal cell line (HT-22) and mouse 
primary cortical neurons.  A rapid and profound mitochondrial dysfunction was observed after 
as little as 1.5 hours of exposure to TNF-α which preceded cell death.  These findings suggest 
that the damaging effect of TNF-α may be due to the impairment of neuronal mitochondrial 






2.3. Materials and Methods 
Cell Culture   
An immortalized mouse hippocampal cell line, HT-22, was cultured in Hyclone DMEM/high 
glucose (Fisher Scientific, Waltham, MA) with 10% fetal bovine serum (FBS) (Atlanta 
Biologicals, Flowery Branch, GA) and 1% penicillin/streptomycin (Fisher Scientific).  The HT-
22 mouse hippocampal neuronal cell line was provided by The Salk Institute for Biological 
Research (La Jolla, CA), and cell passages 15 – 23 were used.   When HT-22 cells were at least 
80% confluent, the cells were trypsinized and spun down at 1500 RPM for 3 minutes.  The cells 
were counted with Nexcelom Bioscience Cellometer AutoT4 (Lawrence, MA).   Primary mouse 
cortical neurons were purchased from Life Technologies (Carlsbad, CA) and cultured in 




Recombinant Mouse TNF-α was purchased from R&D Systems (Minneapolis, MN) and 
reconstituted at 50 µg/ml in phosphate buffered saline (PBS) containing 0.1% bovine serum 
albumin (BSA).  Dilutions were made in Hyclone DMEM/high glucose with 10% FBS and 1% 
penicillin/streptomycin to obtain concentrations of 1, 10, 100, and 1000 pg/ml.  The media was 
removed from each well by gentle aspiration.  After removing the media, 100 ul of Hyclone 
DMEM/high glucose or the various concentrations of TNF-α were added for either 1.5, 3, 6, or 
12 hours.  These time points were chosen based upon the post-stroke increase in TNF-α in serum 
patients and in the brains of animal models (Liu et al., 1994; Botchkina et al., 1997; Zaremba 
and Losy, 2001; Intiso et al., 2003).   For primary mouse cortical neurons, TNF-α at 
concentrations of 0, 100 and 1000 pg/ml were added for 1.5, 3, 6 and 24 hours. 
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Mitochondrial Function Assessment 
15,000 HT-22 cells or 16,000 primary mouse cortical neurons were seeded in a XFe96 cell 
culture microplate.  HT-22 cells were treated with 1- 1000 pg/ml of TNF-α (6 replicates per 
treatment condition) 24 hours after seeding.  Primary mouse cortical neurons were treated with 
100 or 1000 pg/ml of TNF-α 3 days after seeding.  After treating with TNF-α, mitochondrial 
function was assessed with the XFe 96 Analyzer (Seahorse Bioscience, North Billerica, MA) 
using a Mito Stress test kit at 1.5, 3, 6, and 12 hours (HT-22 cells) or 1.5, 3, 6, and 24 hours 
(primary neurons).  Non-mitochondria derived oxygen consumption rate (OCR) was measured 
using the first measurement after addition of rotenone and antimycin a.  To calculate basal 
respiration, the measurement prior to oligomycin addition was subtracted from non-
mitochondria derived OCR.  Proton leak was measured using the third measurement after 
oligomycin injection subtracted from non-mitochondrial derived OCR.  ATP production was 
measured from subtracting proton leak from basal respiration.  Maximal respiration was 
calculated using the first measurement after FCCP injection subtracted from non-mitochondria 
derived OCR.   
 
Cell Viability  
Cell viability was assessed using Calcein AM (Life Technologies), and reconstituted at 2mM in 
DMSO.  15,000 HT-22 cells or 16,000 primary mouse cortical neurons were seeded in a black-
walled clear bottom 96 well plate.  HT-22 cells were exposed to 1 – 1000 pg/ml of TNF-α and 
the primary mouse cortical neurons were treated with 100 or 1000 pg/ml of TNF-α.  After 
exposure to TNF-α for 1.5, 3, 6, and 12 hours (HT-22 cells) or 1.5, 3, 6, and 24 hours (primary 
neurons), the plate was washed three times with PBS 1X.  100 ul of 1uM Calcein AM was added 
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to the wells.  The plate was incubated at room temperature in the dark for 30 minutes. The plate 
was read using a BioTek Synergy H1 Hybrid reader (Winooski, VT).   
 
Flow Cytometry 
HT-22 cells were grown to 90% confluence, a single cell suspension was made using cell 
dissociation buffer, and the cells were fixed in 10% formaldehyde for 30 minutes and 
subsequently permeabilized in 70% ethanol for 30 minutes on ice.  To reduce non-specific 
antibody binding, HT-22 cells were blocked in 3% BSA in PBS for 15 minutes and subsequently 
incubated with 1ug  PE anti-mouse CD120a (TNF R Type I/p55) or PE anti-mouse CD120b 
(TNF R Type II/p75)  from Biolegend (San Diego, CA).  Data were acquired by counting 10,000 
events and analyzed using FACSCalibur (BD Biosciences, San Jose, CA) to determine the 
presence or absence of TNF-R1 and/or TNF-R2.   
 
TNF-R1 or TNF-R2 antibody Treatment 
HT-22 cells were pre-treated for 1 hour with 4, 6, or 8 ug/ml of LEAFLM Purified anti-mouse 
CD120a (TNF R Type I/p55), 4, 6, or 8 ug/ml of LEAFLM Purified anti-mouse CD120b (TNF R 
Type II/p75), or 8 ug/ml of LEAFLM Purified Armenian Hamster IgG Isotype Ctrl from 
Biolegend. Media was removed and cells were then treated with 100 pg/ml of TNF-α for 1.5 
hours or 3 hours.  Cell viability was assessed with Calcein AM at both 1.5 and 3 hours, and 
mitochondrial basal respiration was assessed with the XFe 96 Analyzer from Seahorse 





Caspase 8 and Caspase 3/7 Activity 
Caspase 8 and Caspase3/7 activity was assessed with the Caspase-Glo TM 8 and Caspase-Glo TM 
3/7 assay kits (Promega, Madison, WI) after treating HT-22 cells with 1, 10, 100, 1000 pg/ml of 
TNF-α for 1.5 hours.  
 
TMRE Mitochondrial Membrane Potential Assay 
Mitochondrial membrane potential was assayed using a TMRE mitochondrial membrane 
potential assay (Abcam,Cambridge, MA) by addition of 300 nM TMRE and 20 μM FCCP after 
treating HT-22 cells with 1, 10, 100, 1000 pg/ml of TNF-α for 1.5 hours. 
 
Cytochrome c release from mitochondria to cytosol  
After exposure to 100 or 1000 pg/ml of TNF-α for 3, 6, 12, and 24 hours, HT-22 cells were 
fractioned into cytosolic and mitochondrial fractions using the Mitochondrial/Cytosol 
Fractionation Kit (Biovision, Milpitas, CA).  The protein concentration of each fraction was 
determined using the Pierce 660nm protein assay (Thermo Scientific, Waltham, MA).  
Cytochrome c levels in the cytosolic and mitochondrial fractions were determined using a 
rat/mouse cytochrome c Quantikine ELISA (R&D Systems, Minneapolis, MN).  Percentage 
release of cytochrome c was calculated using the following equation: total cytosolic cytochrome 
c/ (cytosolic + mitochondrial cytochrome c) (Tanaka et al., 2004).   
 
Statistical Analysis  
One-way ANOVA and post hoc analyses (Dunnett or Trend for linear analysis) were used to 
analyze differences among groups using GraphPad Prism 5 software. Statistical significance was 
determined at a p < 0.05.   
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2.4. Results  
TNF-α caused a decrease in mitochondrial function at 1.5, 3, 6, and 12 hours in HT-22 cells 
Figure 2.1 (A, C, E, G) and Supplemental Figure 1 show the dose-dependent decrease in basal 
respiration, ATP production, and maximal respiration at 1.5, 3, 6, and 12 hours of TNF-α 
exposure.  At 1.5 hours, basal respiration, ATP production, and maximal respiration decreased 
by approximately 30%, and 40% at 100 and 1000 pg/ml TNF-α, respectively (Figure 2.1A and 
Supplemental Figure 2.1A).   At 3 and 12 hours, but not 6 hours, the magnitude of the dose-
dependent reduction in basal respiration, ATP production, and maximal respiration induced by 
TNF-α was increased (Figure 2.1 C, E, G and Supplemental Figure B – D).  
 
TNF-α caused a delayed decrease in cell viability in HT-22 cells  
Based on our observation of decreased mitochondrial function as early as 1.5 hours of TNF-α 
exposure, we determined if the decrease in mitochondrial function preceded cell death.   We did 
not observe a significant decrease in cell viability after 1.5 hours of exposure to TNF-α (Figure 
2.1 B).  However, cell viability began to decrease after 3 hours by approximately 30% at doses 
of 100 and 1000 pg/ml of TNF-α (Figure 2.1 D).  Additionally, cell viability decreased 
significantly at 6 and 12 hours (Figure 2.1 F and H).  At 6 hours, 100 and 1000 pg/ml of TNF-α 
caused a decrease in cell viability of approximately 37%.  At 12 hours, 10, 100, and 1000 pg/ml 
caused a decrease in cell viability of approximately 50%.   
 
TNF-α caused a rapid decrease in mitochondrial function and a delayed decrease in cell 
viability in mouse primary cortical neurons 
To confirm the rapid and profound effects of low doses of TNF-α on mitochondrial function was 
not specific to a transformed cell line, we exposed mouse primary cortical neurons to low doses 
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of TNF-α for 1.5, 3, 6, and 24 hours.  After exposure to 100 pg/ml and 1000 pg/ml of TNF-α for 
1.5 hours, basal respiration was decreased by 48% and 61%, respectively without causing cell 
death (Figure 2.2 A and B).  Acute exposure to low doses of TNF-α did not decrease cell 
viability until 24 hours after exposure to 1000 pg/ml of TNF-α (Figure 2.2 H).  Since TNF-α 
rapidly decreases mitochondrial function prior to cell death in both HT-22 cells and mouse 
primary cortical neurons, we used the HT-22 cell line to determine the mechanism by which 
TNF-α rapidly affects mitochondrial function.   
 
HT-22 cells express TNF-R1 and TNF-R2 
It is known that TNF-α mediates its effects through TNF-R1 and TNF-R2.  There is expression 
of TNF-R1 on all cell types, while expression of TNF-R2 is primarily on hemopoietic and 
endothelial cells (Maddahi et al., 2011).  To determine the expression pattern of TNF-α receptors 
on  HT-22 cells, flow cytometry analysis of HT-22 cells with antibodies specific for TNF-R1 
and TNF-R2 was performed.  HT-22 cells expressed both TNF-R1 (24.56%) and TNF-R2 
(87.17%) under normal culture conditions (Supplemental Figure 2.2).    
 
TNF-α exerts its neurotoxic effects through TNF-R1 
Pre-treating HT-22 cells with 4, 6, or 8 ug/ml of TNF-R1 antibody for 1 hour ameliorated the 
TNF-α induced decrease in mitochondrial basal respiration (Figure 2.3 A), ATP production, and 
maximal respiration (data not shown) at 1.5 hours.  As observed in Figure 2.1 B, TNF-α did not 
kill HT-22 cells at 1.5 hours (Figure 2.3 B and E).  The decrease in cell viability caused by 100 
pg/ml of TNF-α at 3 hours was ameliorated when TNF-R1 was blocked (Figure 2.3 C).  
However, when HT-22 cells were pre-treated with 4, 6, or 8 ug/ml of TNF-R2 antibody, the 
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neurotoxic effects of TNF-α on mitochondrial basal respiration at 1.5 hours (Figure 2.3 D) or 
cell viability at 3 hours (Figure 2.3 F) was not affected.   
 
TNF-α caused an increase in caspase 8 activity but not caspase 3/7 activity in HT-22 cells 
After exposure to 1, 10, 100, 1000 pg/ml of TNF-α for 1.5 hours, caspase 8 and caspase 3/7 
activity was assessed with caspase 8 and caspase 3/7 luciferase assays.  TNF-α caused a dose-
dependent increase in caspase 8 activity (Figure 2.4 A); however, caspase 3/7 activity was not 
affected by TNF-α exposure at this early time (Supplemental Figure 2.3).  At the highest TNF-α 
concentration of 1000 pg/ml, caspase 8 activity was increased by 46%.   
 
TNF-α caused a decrease in mitochondrial membrane potential in HT-22 cells 
Mitochondrial membrane potential dissipation results from the activation of caspases; thus, the 
increase in caspase 8 activity after 1.5 hours of exposure to TNF-α led us to hypothesize that 
TNF-α causes mitochondrial membrane potential to decrease as a result of the activation of 
caspase 8.  TNF-α exposure for 1.5 hours resulted in a significant dose-dependent decrease in 
mitochondrial membrane potential (Figure 2.4 B), and there was a significant correlation 
between the increase in caspase 8 activity and decrease in mitochondrial membrane potential 
(Figure 2.4 C).   
 
TNF-α induced cytochrome c release from mitochondria in HT-22 cells 
After exposure to 100 and 1000 pg/ml of TNF-α for 3, 6, 12, and 24 hours, there was a dose-
dependent increase in cytochrome c release from mitochondria (Figure 2.5).  Exposure to TNF-α 
for 3, 12, and 24 hours with 100 and 1000 pg/ml TNF-α resulted in a significant increase in 
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cytochrome c release, and after exposure for 6 hours only 1000 pg/ml of TNF-α resulted in a 
significant increase in cytochrome c release (p < 0.05).  
 
2.5. Discussion 
The present study shows, for the first time, that TNF-α rapidly and profoundly reduces neuronal 
cell mitochondrial function.  It is widely accepted that mitochondria play a role in neuro-
inflammation and neurodegenerative CNS disorders such as multiple sclerosis, Alzheimer’s 
disease, and Parkinson’s disease (Di Filippo et al., 2010).  With an insult like ischemic stroke, 
activation of microglia occurs that leads to the release of TNF-α along with other pro-
inflammatory cytokines (Davalos et al., 2005).  Pro-inflammatory cytokines can activate 
mitochondria-induced apoptosis leading to cell death (Huang et al., 2005).  Our findings suggest 
that TNF-α exposure caused neuronal mitochondrial dysfunction as expressed by decreased 
mitochondrial respiration as early as 1.5 hours of exposure.   
 
Neurons have a high ATP demand (Zhu et al., 2012), and a temporary reduction in ATP 
production results in a profound decrease in neuronal viability (Simpkins et al., 2010).  Fiskum 
et al. (1999) hypothesized that neuronal death that occurs at the core of an infarct after ischemia 
results from the decrease in mitochondrial and glycolytic ATP production. TNF-α is known to 
exacerbate infarct size in pre-clinical models of stroke, and this may be due to the profound and 
rapid decrease in ATP production, caused by TNF-α release in the evolving ischemic core. 
Although TNF-R2 is primarily expressed on immune cells, and the expression of TNF-R1 is 
constitutive on all cell types, HT-22 cells express both receptors (Maddahi et al., 2011).  TNF-
R2 plays a major role in the lymphoid system and requires membrane bound TNF-α for full 
activation; thus, we hypothesized that TNF-α affects mitochondrial function through TNF-R1 
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because soluble TNF-α signaling is primarily through TNF-R1 (Wajant et al., 2003; Maddahi et 
al., 2011).  Furthermore, there is no correlation between the number of receptors present on a 
cell and the magnitude of the TNF-induced response (Beyaert and Fiers, 1994).  Blocking TNF-
R1 ameliorated the neurotoxic effects of TNF-α on mitochondrial respiration and cell viability, 
confirming TNF-α exerts neurotoxic effects through TNF-R1 not TNF-R2.  To further 
understand the neurotoxic mechanisms of TNF-α, we assessed caspase 8 and caspase 3/7 activity 
because TNF-α can signal through TNF-R1 and activate caspase 8 or caspase 3/7 (Baud and 
Karin, 2001; McCoy and Tansey, 2008).  The activation of caspase 8 causes mitochondrial-
induced apoptosis through the cleavage of Bcl-2-associated X protein (BAX) and BH3 
interacting-domain death agonist (BID) (Aggarwal, 2003; McCoy and Tansey, 2008).  Caspase 8 
activity was increased in a dose-dependent manner after exposure to TNF-α for 1.5 hours; 
however, caspase 3/7 activity was not affected at this early time.  The increase in caspase 8 
activity led us to hypothesize that mitochondrial membrane potential should decrease if caspase 
8 is initiating mitochondrial-induced apoptosis (Green and Kroemer, 2004).  The TMRE 
mitochondrial membrane potential assay showed a significant dose-dependent decrease in 
mitochondrial membrane potential after 1.5 hour of TNF-α exposure.  Furthermore, with a 
collapse of mitochondrial membrane potential there should be an increase in cytochrome c release 
from the mitochondria, due to the cleavage of BAX and BID (Baud and Karin, 2001; Aggarwal, 
2003; McCoy and Tansey, 2008).  After exposure to 100 pg/ml of TNF-α for 3 and 24 hours, 
there was an 11% and 68% increase in cytochrome c release, respectively, from mitochondria.  
Our observation of a 19.7% decrease in mitochondrial membrane potential and the 30% decrease 
in ATP production at 1.5 hours of treatment with 100 pg/ml TNF-α indicates that sufficient 
cytochrome c is released to induce apoptosis (Sas et al., 2007).  Once cytochrome c is released, 
cytochrome c interacts with apoptotic protease-activating factor-1 (Apaf-1), procaspase-9, and 
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dATP forming an apoptosome (Sas et al., 2007).  The formation of the apoptosome allows for 
the activation of caspase-9, which activates procaspase-3, and results in the induction of 
apoptosis (Sas et al., 2007).   
 
HT-22 cells and primary mouse cortical neurons both showed a rapid mitochondrial impairment 
and subsequent cell death in response to low concentrations of TNF-α. However, there was a 
notable difference between the two cell types in the timing of the TNF-α induced cell death. 
Whereas HT-22 cells died within 3 hours of exposure, primary neurons showed cell loss only at 
24 hours. The reason for this delayed response of primary neurons is not clear, but is consistent 
with the comparative resistance of primary neurons to TNF-α in other studies (Reimann-Philipp 
et al., 2001; Zhao et al., 2001). We suspect, but do not have evidence to support, that primary 
neurons may have inherent defense mechanisms that resist the neurotoxic effects of a single 
cytokine, like TNF-α  (Tamatani et al., 1999).  
 
Numerous studies reported an association between increased levels of TNF-α mRNA and protein 
and an exacerbation of ischemic injury (Di Filippo et al., 2010).  Administration of TNF-α-
blocking antibodies or soluble TNF-R1 prior to inducing stroke reduces infarct volume 
(Murakami et al., 2005; Di Filippo et al., 2010).  Our findings may provide the mechanism of 
TNF-α exacerbation of stroke damage and shows that TNF-α elicits neurotoxic effects by 
inducing a rapid mitochondrial dysfunction mediated through TNF-R1 signaling subsequently 
activating caspase 8 and leading to the release of cytochrome c.   
Current clinical treatment of ischemic stroke concentrates on dissolving and/or removing the 
clot, without much focus on the secondary damage that occurs as part of the inflammatory 
ischemic cascade (Works et al., 2013).  Inflammation is known to play a major role in the 
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pathophysiology of stroke and progression of damage post-stroke (Vila et al., 2000a; Iadecola 
and Anrather, 2011).  The identification of a new therapeutic to reduce brain damage due to 
inflammation post-stroke would be clinically useful. However, TNF-α has both pro-apoptotic 
and anti-apoptotic activities, and both roles are important physiologically (Aggarwal, 2003). 
When the expression of TNF-α is profound and prolonged, such as after stroke, it has harmful 
effects (Aggarwal, 2003).  Thus, understanding the neurotoxic mechanism of TNF-α is 
important to further advance its potential as a therapeutic target. 
 
As with all in vitro studies, our studies have some limitations, and we interpreted our results 
with caution.  First, TNF-α was administered at discrete doses (1-1000 pg/ml) for 1.5 to 24 
hours.  Post- stroke concentrations change over time and are elevated in patients within 6 hours 
of symptom onset and stay elevated for up to 10 days (Zaremba and Losy, 2001; Intiso et al., 
2003).  Furthermore, TNF-α mRNA is increased in the ischemic core within 1 hour, and TNF-α 
immunoreactive protein is seen within 2-6 hours in the brain after middle cerebral artery 
occlusion, (MCAO) in preclinical models (Liu et al., 1994; Botchkina et al., 1997).  We 
observed mitochondrial impairment with clinically relevant concentrations of TNF-α over a 
critical time window post-stroke.  An additional limitation is the use of cell culture models such 
as a transformed cell line and a primary mouse neuronal culture.  Both cell types are models for 
neurons, but do not have astrocytes, microglia, or endothelial cells; thus, the results should be 
taken with caution.  In view of the similarity between the two models, we believe we have 
modeled the effects of TNF-α on nerve cells.  Finally, we did not evaluate cleavage of BAX and 
BID.  We assumed the cleavage occurred because caspase 8 cleaves BAX and BID, resulting in 
cytochrome c release.   Our results support that exposure to TNF-α at 1.5 hours results in an 
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increase in caspase 8 activity, and by 3 hours we observed a significant release of cytochrome c 
from the mitochondria into the cytosol.   
 
This study shows, for the first time, a rapid and profound mitochondrial dysfunction in neurons 
with acute exposure to low doses of TNF-α.  This neurotoxic effect of TNF-α appears to be 
mediated by TNF-R1, leading to caspase activation, mitochondrial membrane potential collapse, 
and mitochondrial release of cytochrome c.  Collectively these data help to elucidate the 
neurotoxic mechanisms of TNF-α, and thereby, provides potential targets for cytokine directed 


















Figure 2.1:  Effects of TNF-α on basal respiration and cell viability in HT-22 cells.  (A) Basal 
respiration after exposure to TNF-α for 1.5 hours. (B) Cell viability after exposure to TNF-α for 
1.5 hours.  (C) Basal respiration after exposure to TNF-α for 3 hours.  (D) Cell viability after 
exposure to TNF-α for 3 hours.  (E) Basal respiration after exposure to TNF-α for 6 hours.  (F) 
Cell viability after exposure to TNF-α for 6 hours.  (G) Basal respiration after exposure to TNF-
α for 12 hours.  (H) Cell viability after exposure to TNF-α for 12 hours. Analysis of variance and 
Dunnett post-hoc tests were used to assess significance. * p < 0.05; ** p < 0.01; *** p < 0.001.  
Depicted are mean + SEM for n = 6/group. 
 
Figure 2.2:  Effects of TNF-α on basal respiration and cell viability in mouse primary cortical 
neurons. (A) Basal respiration after exposure to TNF-α for 1.5 hours. (B) Cell viability after 
exposure to TNF-α for 1.5 hours.  (C) Basal respiration after exposure to TNF-α for 3 hours.  (D) 
Cell viability after exposure to TNF-α for 3 hours.  (E) Basal respiration after exposure to TNF-α 
for 6 hours.  (F) Cell viability after exposure to TNF-α for 6 hours.  (G) Basal respiration after 
exposure to TNF-α for 24 hours.  (H) Cell viability after exposure to TNF-α for 24 hours.  
Analysis of variance and Dunnett post-hoc tests were used to assess significance. * p < 0.05; ** 
p < 0.01; *** p < 0.001.  Depicted are mean + SEM for n = 6/group. When SEM is not depicted, 
it is too small for representation.   
 
Figure 2.3:  Effects of blocking TNF-R1 or TNF-R2 on TNF-α induced changes in 
mitochondrial basal respiration and cell viability.  (A) Effects of TNF-R1 antibody on TNF-α 
induced changes in mitochondrial basal respiration at 1.5 hours.  (B)  Effects of TNF-R1 
antibody on TNF-α induced changes in cell viability at 1.5 hours. (C)  Effects of TNF-R1 
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antibody on TNF-α induced changes in cell viability at 3 hours. (D)  Effects of TNF-R2 antibody 
on TNF-α induced changes in mitochondrial basal respiration at 1.5 hours.  (E)  Effects of TNF-
R2 antibody on TNF-α induced changes in cell viability at 1.5 hours. (F) Effects of TNF-R2 
antibody on TNF-α induced changes in cell viability at 3 hours.  Analysis of variance and 
Dunnett post-hoc tests were used to assess significance, * p< 0.05, *** p< 0.001; ## p < 0.01; 
### p< 0.001; * compared to Vehicle; # compared to 100 pg/ml TNF-α; Depicted are mean + 
SEM for n = 6/group. 
 
 Figure 2.4:  (A) Effects of 1.5 hours of exposure to TNF-α on caspase 8 activity.  Analysis of 
variance and Dunnett post-hoc tests were used to assess significance, *** p < 0.001 (B) Effects 
of 1.5 hours of treatment with TNF-α on mitochondrial membrane potential.  Analysis of 
variance with post-test for linear trend found a significant dose-dependent decrease in 
mitochondrial membrane potential, R square = 0.3571, p = 0.0163  Pearson’s correlation 
between caspase 8 activity and mitochondrial membrane potential.  R square = 0.9437, p = 
0.086.  Depicted are mean + SEM for n = 6/group. 
 
Figure 2.5:  Effects of TNF-α on cytochrome c release.  (A) Exposure to TNF-α for 3 hours.  (B) 
Exposure to TNF-α for 6 hours.  (C) Exposure to TNF-α for 12 hours.  (D) Exposure to TNF-α 
for 24 hours. Analysis of variance and Dunnett post-hoc tests were used to assess significance. * 
p < 0.05; ** p < 0.01; *** p < 0.001.  Depicted are mean + SEM for n = 6/group.  When SEM is 



























Supplemental Figure Legends 
Supplemental Figure 2.1:  Effects of TNF-α on ATP production and maximal respiration.  (A) 
Exposure to TNF-α for 1.5 hours.  (B) Exposure to TNF-α for 3 hours.  (C) Exposure to TNF-α 
for 6 hours.  (D) Exposure to TNF-α for 12 hours. Analysis of variance and Dunnett post-hoc 
tests were used to assess significance. * p < 0.05; ** p < 0.01; *** p < 0.001.  Depicted are mean 
+ SEM for n = 6/group.  
 
Supplemental Figure 2.2:  Flow cytometry analysis of HT-22 cell expression of TNF-R1 and 
TNF-R2. 
 
Supplemental Figure 2.3:  Effects of 1.5 hours of exposure to TNF-α on caspase 3/7 activity.  
Analysis of variance did not show a significant difference among the groups.  Depicted are mean 





















Supplemental Figure 2.1 
57  
 

















































Mitochondrial Crisis in Cerebrovascular 
Endothelial Cells Opens the Blood-Brain 
Barrier 
 
Danielle N. Doll, Heng Hu, MD, Jiahong Sun, Sara E. 











Doll DN, Hu H, Sun J, Lewis SE, Simpkins JW, Ren X. (2015) 
Mitochondrial Crisis in Cerebrovascular Endothelial Cells 






Background and Purpose--The blood-brain barrier (BBB) is a selectively permeable 
cerebrovascular endothelial barrier that maintains homeostasis between the periphery and central 
nervous system (CNS). BBB disruption is a consequence of ischemic stroke and BBB 
permeability can be altered by infection/inflammation, but the complex cellular and molecular 
changes that result in this BBB alteration need to be elucidated to determine mechanisms.  
Methods—Infection mimic (LPS) challenge on infarct volume, BBB permeability, infiltrated 
neutrophils and functional outcomes following murine transient middle cerebral artery occlusion 
(tMCAO) in vivo; mitochondrial evaluation of cerebrovascular endothelial cells (CVECs) 
challenged by LPS in vitro; pharmacological inhibition of mitochondria on BBB permeability in 
vitro and in vivo; the effects of mitochondrial inhibitor on BBB permeability, infarct volume and 
functional outcomes following tMCAO. 
Results--We report here that LPS worsens ischemic stroke outcome and increases BBB 
permeability following tMCAO in mice.  Further, we elucidate a novel mechanism that 
compromised mitochondrial function accounts for increased BBB permeability as evidenced by: 
LPS-induced reductions in oxidative phosphorylation and subunit expression of respiratory 
chain complexes in CVECs, a compromised BBB permeability induced by pharmacological 
inhibition of mitochondrial function in CVECs in vitro and in an in vivo animal model, and 
worsened stroke outcomes in tMCAO mice following inhibition of mitochondrial function.  
Conclusions--We concluded that mitochondria are key players in BBB permeability. These 
novel findings suggest a potential new therapeutic strategy for ischemic stroke by endothelial 




The blood-brain barrier (BBB) is a highly specialized vascular interface that maintains 
homeostasis in brain by separating the blood compartment from the central nervous system 
(CNS). Disruption of cerebrovascular endothelial cells not only allows entry of unwanted solutes 
into brain, but also disrupts the normal CNS entry route of critical nutrients (Rubin and Staddon, 
1999; Gonzalez-Mariscal et al., 2000). Disruption and/or dysfunction of the BBB has been 
observed in cerebrovascular diseases and neurodegenerative disorders such as stroke, 
Alzheimer’s disease (AD), Parkinson disease (PD), Huntington’s disease and epilepsy (Tajes et 
al., 2014). 
 
Stroke is the second leading cause of death and the leading cause of disability worldwide (Feigin 
et al., 2014). It is estimated that 30-40% of all strokes occur during or recently after an acute 
infection (Grau et al., 1995b). Acute infections initiate rapid inflammation, and post-stroke 
infections worsen outcomes in patients (Grau et al., 1995a) and in animal models (McColl et al., 
2007). However, the mechanisms of this exacerbation by infection on acute stroke outcome are 
not completely understood. 
 
Ischemia and reperfusion events result in complex cellular and molecular changes that further 
need to be elucidated.  Thus far, studies have provided evidence that the release of oxidants, 
proteolytic enzymes and inflammatory cytokines alter BBB permeability.  The BBB excludes 
the majority of bacteria; however, similar to ischemia and reperfusion, inflammation induced by 
bacteria alters BBB permeability.  Lipopolysaccharide (LPS) has been shown to disrupt the BBB 
in vivo and in vitro, however, how LPS exerts its effects on the BBB is under debate (Banks and 
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Erickson, 2010).  Previous studies found that an LPS challenge results in a larger infarct volume 
(McColl et al., 2007), impairs survival and disrupts BBB (Denes et al., 2011) in experimental 
stroke models, through mechanisms that are proposed to involve cytokines.  
 
In the present study, we provide the first evidence that the exacerbation of stroke outcome by a 
bacterial infection mimic is due to a novel mechanism of compromised cerebrovascular 
endothelial mitochondrial function. Potential deleterious mitochondrial responses to ischemia 
have been observed, such as rapid changes in ATP, the release of cytochrome c, and the 
induction of the mitochondrial permeability transition (Sims and Anderson, 2002; Sims and 
Muyderman, 2010). It is apparent mitochondria play a pivotal role during ischemia; however, 
the contributions of mitochondrial dysfunction in non-neuronal cells and the interactions 
between these cells and neurons are poorly understood. Additionally, the involvement of 
mitochondria in ischemic damage has not been fully elucidated. We show that pharmacological 
disruption of endothelial mitochondrial function recapitulates all aspects of the LPS exacerbation 
of stroke, including disruption of the BBB, and worsening of stroke outcome. This discovery 
could provide a previously unknown mitochondrial-dependent mechanism for acute stroke 
damage that may offer new therapeutic directions for the treatment of acute stroke. 
3.3. Methods 
Mice 
All procedures were conducted according to the criteria approved by the Institutional Animal 
Care and Use Committees (IACUC) at the West Virginia University (WVU). C57/BL6J male 




All surgical anesthesia was induced with 4-5% isoflurane until the animal showed no response to 
a toe pinch, and was maintained with 1-2% isoflurane via face-mask in O2-enriched air.  
 
Randomization and blinding of the animal experiments 
To assign pre-treatments of mice, we numbered the animals and applied a simple randomization 
by using excel-generated random numbers. To avoid biases, we also assured that different pre-
treatments were performed on the same day. The experimenters were blinded to the pre-
treatments and data analysis. 
 
Drug administration 
In a subgroup of mice, LPS (Escherichia coli 055:B5, 100 μg/kg, Sigma) dissolved in saline (B. 
Braun Medical Inc. Irvine, California) was injected intraperitoneally 30 min prior to tMCAO or 
sham surgery. In another subgroup of mice, rotenone (1 mg/kg, Sigma) was administered 
intraperitoneally 30 min prior to tMCAO. In the EA model, rotenone (2 mg/ml, 2 μl) was 
topically applied to the epidural membrane. An equal volume of saline was administered to 
control mice.  
 
Ischemic model and sham surgery 
We performed focal cerebral ischemia for 30 min or 60 min by occlusion of the right middle 
cerebral artery with a 6.0 monofilament suture (Doccol, Sharon, Massachusetts). We used laser 
Doppler flowmetry (Moor instruments, United Kingdom) to detect regional cerebral blood flow 
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and confirm a successful occlusion (>70% decrease in flow). Rectal body temperature was 
maintained at 37 ± 0.5 °C during surgery. Mice were euthanized at several time points as 
indicated in the text.  
 
Neurological deficits 
Neurologic deficit was determined daily before and after tMCAO according to a 0-5 point scale 
neurological score system as published (Harhausen et al., 2010). 
 
Epidural application (EA) model 
We induced anesthesia with 4% isofluorane and maintained with 1% isofluorane. We placed the 
animal in a prone position under a stereo dissecting microscope and made an incision down the 
midline of the head and retracted the skin then removed the fascia from the skull. Using a sharp 
blade, we thinned an area of the skull approximately 0.3-0.5 mm in diameter, divided the thinned 
area into several segments, performed a craniotomy by gently removing the thinned skull 
segments, applied drug or vehicle, and closed the incision. 
 
Exclusion criteria for animal experiments  
The exclusion criteria for tMCAO were: 1) regional cerebral blood flow decreases <70% during 
occlusion as detected by laser Doppler flowmetry; 2) surgery time lasts more than 30 minutes; 3) 
no neurological deficits 3 hour after MCAO (neurological score 0); 4) no infarction in the MCA 
territory on TTC staining; 5) subarachnoid hemorrhage on postmortem examination; and 6) 
substantial ambient temperature change in the animal facility. Animals which died prior to the 
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planned time of assessments were postmortem examined for subarachnoid hemorrhage, and the 
mortality was recorded.  
The exclusion criteria for EA model were: 1) damaged epidural membrane, 2) bleeding from the 
epidural membrane; 3) the leakage of cerebrospinal fluid from the epidural membrane; 4) body 
temperature >39.5°C within post-surgery 3 hours; and 5) death. 
In this study, 7 mice were excluded: 2 mice (one vehicle and one LPS pre-treatment) because of 
subarachnoid hemorrhage, 4 mice (2 vehicle and 2 LPS pre-treatment) because the animal 
facility air conditioner broke down on the day that the experiments were performed, 1 mouse 
(pre-treated with rotenone) because LDF did not reach 70% reduction during the occlusion. The 
animal numbers included in the results are 18 vehicle and 23 LPS for 30 min tMCAO mice (4 
LPS pretreated mice died), 12 vehicle and 12 rotenone for 60 min tMCAO mice, 5 vehicle and 5 
rotenone for EA mice. No animals were excluded in EA model. 
 
Analysis of brain infarct volume 
Mice were euthanized with isofluorane. We removed the brains and cut 2 mm coronal sections 
with a mouse brain matrix. We stained the sections with 2% 2,3,5-triphenyltetrazolium chloride 
(TTC, Sigma, Saint Louis, Missouri) in phosphate buffer solution (PBS) at 37°C for 30 minutes 
then fixed the tissue in 10% formalin phosphate buffer for digital photograph. We analyzed the 
digitized image of each brain section using a computerized image analysis software (ImageJ, 
NIH) in a double blinded manner. To minimize the effect of brain edema, the volume was 




Blood-brain barrier (BBB) permeability assay in vivo 
The permeability of the BBB was determined by measuring the penetration of Evans blue 
(Sigma) in the brain tissue. Evans blue (2% in saline, 4 ml/kg body weight) was administered 
intravenously via the tail vein one hour prior to measurement. The anesthetized animals were 
perfused transcardially with saline before sampling. Each sample was weighed and homogenized 
with 400 µl PBS, then precipitated by 50% trichloroacetic acid overnight. The samples were 
centrifuged for 30 minutes at 10,000 rpm to pellet brain tissue. Absorption of the supernatant 
was measured at a wavelength of 610 nm with a plate reader (BioTek, Winooski, Vermont). The 
extravasation of Evans blue was quantified as μg/g brain tissue with an Evans blue standardized 
curve. 
 
Isolation of immune cells in the blood, spleen and brain 
Blood was collected via cardiac puncture then brain and spleen were sampled after transcardial 
perfusion with saline. Peripheral blood mononuclear cells and splenocytes were prepared by 
using red cell lysis buffer (eBioscience, San Diego, California). For brain immune cells, the 
forebrain was dissected from the cerebellum and suspended in RPMI-1640 medium (Corning, 
Pittsburgh, Pennsylvania). The suspension was digested with type IV collagenase (1 mg/ml, MP 
Biomedicals, Solon, Ohio) and DNase I (50 μg/ml, Roche Diagnostics, Indianapolis, Indiana) at 
37°C for 45 min, then immune cells were isolated by 37–70% Percoll (GE Healthcare, 
Piscataway, New Jersey) density gradient centrifugation and collected from the interface. Single 
cell suspension was washed with staining buffer (PBS containing 0.1% NaN3 and 2% FCS) and 
stained with CD45 (30-F11, eBioscience), CD11b (M1/70, eBioscience), and Gr1 (IA8, BD 
Bioscience). Propidium iodide (PI, 2 μg/ml, Sigma) was used to exclude dead cells. Appropriate 
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isotype control antibodies were applied to set quadrants for calculating the percentage of positive 




The bEnd.3 cell line (CRL-2299 from ATCC, Manassas, Virginia) was originally derived from 
mouse brain cortex endothelial cells and confirmed by the observed major phenotypic features of 
the blood-brain barrier.(Brown et al., 2007a) Passages 25-30 were used in the study. The bEnd.3 
cells were routinely grown in high glucose Dulbecco’s modified Eagle’s medium (DMEM, 
ATCC) supplemented with 10% FCS and 1% penicillin/streptomycin (Hyclone, South Logan, 
Utah) at 37 °C in 5% CO2 humid atmosphere. Mouse primary brain microvascular endothelial 
cells (B129-7023 from CellBiologics, Chicago, Illinois) were routinely grown in complete 
Endothelial Cell Medium (Cell Biologics, M1168) at 37 °C in 5% CO2 humid atmosphere.   
  
Blood-brain barrier permeability assay in vitro 
Permeability assays were performed in triplicate as follows: 1.5×105 endothelial cells were 
grown on transwell inserts (pore size: 0.4 mm, diameter: 6.5mm, Millipore, Darmstadt, 
Germany) for two days, 250 µg/ml FITC labelled dextran FD-70 (70 kDa, Sigma) was added to 
the apical side of the filters and the medium in the basolateral compartment was sampled every 
15 min for 2 hours. The FD-70 permeability through the cultured endothelial monolayer was 
determined directly by analysis of the apparent permeability coefficient (Papp).(Artursson, 
1990) The concentration of FD-70 was determined with an FD-70 standard curve on plate reader 
(Ex. 490 nm, Em. 515 nm). Papp (cm/s) was calculated.  
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Oxygen Consumption 
Oxygen consumption rate (OCR) was measured at 37 °C using an XF96e extracellular analyzer 
(Seahorse Bioscience, North Billerica, Massachusetts) according to the manufacturer’s 
instructions. Briefly, the bEnd.3 cells or primary endothelial cells were seeded into Seahorse 
Bioscience XF96e cell culture plates (16,000 cells/well) in 80 μl medium and allowed to adhere 
and grow overnight in the 37 °C humidified incubator with 5% CO2. Then the cells were 
supplied with 80 µl medium with or without LPS (concentration varies as indicated in the text) 
and cultured for additional 24 hours. For the measurements of extracellular flux, the medium 
was changed 1 h prior to the start of the extracellular flux assay to un-buffered (pH 7.4) DMEM 
containing 2 mM GlutaMax, 1 mM sodium pyruvate, and 25 mM glucose and incubated at 37 °C 
without CO2. Oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), 
rotenone and antimycin A (all from Sigma) and 10× dilutions were prepared for the assays. A 
sensor cartridge was loaded with 20 µl of oligomycin (10 µM) into Port A, 20 µl of FCCP (30 
µM) into Port B, 20 µl of Rotenone (20 µM) and antimycin A (20 µM) into Port C. The Sensor 
cartridge was calibrated and equilibrated and then the protocol was implemented on an XF96e 
Analyzer. This protocol allowed determination of the basal level of oxygen consumption, the 
amount of oxygen consumption linked to ATP production, the maximal respiration capacity, and 
the non-mitochondrial oxygen consumption.  
 
Detect respiratory chain complex I-IV by flow cytometry 
We cultured cells in 6 well plates and treated cells with LPS (1 µg/ml) for 48 hours, then we 
washed cells and performed intracellular staining with an intracellular staining set (cat. 72-5775, 
eBioscience). We stained cells with anti-rabbit-NADH-dehydrogenase-ubiquinone-1-alpha-
69  
subcomplex-assembly-factor-1 (NDUFAF1, sc-292085, 1:100, Santa Crutz), anti-mouse-
NADH-dehydrogenase-ubiquinone-1-subunit-C2 (NDUFC2, sc-393771, 1:100, Santa Crutz), 
anti-mouse-NADH-dehydrogenase-ubiquinone-ironsulfur-protein-2 (NDUFS2, sc-390596, 
1:100, Santa Crutz), anti-rabbit-Succinate-dehydrogenase (SDH, cat.11998, 1:100, Cell 
signaling, Beverly, Massachusetts), anti-rabbit-Cytochrome c (Cyc, cat.4280, 1:100, Cell 
signaling), anti-mouse-Cytochrome c oxidase (COX IV, cat. 4850, 1:100, Cell signaling) 
antibodies for 30 min and labeled the cells with a proper second antibody, PE-anti-rabbit 
(Cat.8885, 1:100, Cell signaling) or PE-anti-mouse (Cat.8887, 1:500, Cell signaling).  We 




To perform the immunohistochemistry co-staining of mitochondria and MyD88, the bEnd.3 cells 
were cultured on cover slips, stained with mitotracker (Life technologies, Grand Island, New 
York) for 30 minutes, washed with PBS then fixed with 2% paraformaldehyde (PFA, 
Polysciences, Inc.) for 10 minutes at 37 °C. The cells were blocked with 5% goat serum staining 
buffer and stained with anti-rabbit-MyD88 (1:200, Abcam, Cambridge, Massachusetts) 
overnight, then washed with PBS and stained with goat-anti-rabbit-FITC (Life technologies) for 
2 hours. The cells were further washed with PBS and mounted on glass slides using prolong gold 
anti-fade reagent (Life technologies). The slides were photographed with confocal LSM 510 





Statistical analysis was performed with Prism 5 software (Graphpad software, La Jolla, 
California). Differences between groups were analyzed by the unpaired Student’s t-test, one way 
ANOVA or two way ANOVA as indicated in the figure legends. 
3.4. Results  
LPS increases cerebral infarction and BBB permeability in stroke 
To test the effects of a bacterial infection mimic on stroke outcome, we performed 
intraperitoneal (i.p.) injections of LPS (100 µg/kg) or saline 30 minutes prior to a 30-minute 
transient middle cerebral artery occlusion (tMCAO) in mice (Fig. 3.1A). LPS challenge 
significantly increased infarct volume in the cortex (P = 0.04), striatum (P = 0.009) and total 
hemisphere (P = 0.04) after 30 minute tMCAO followed by 48 hour reperfusion (Fig. 3.1B, C).  
However, the time course of post-stroke BBB leakage, whether biphasic or progressive, remains 
subject to debate (Sandoval and Witt, 2008; Nag et al., 2011). Using Evans Blue as a tracer, our 
recent work demonstrated biphasic peaks of BBB openings at 6 hours and 72 hours but not at 24 
hours or 48 hours reperfusion following one hour tMCAO (Hu et al., 2014). The 6-hours-peak of 
BBB opening may suggest the early inflammatory infiltration and brain edema in acute stroke. 
Thus, to determine if the acute infection challenge regulates cerebrovascular response to stroke, 
we compared the effects of LPS vs. saline on Evans blue extravasation at 6 hours reperfusion 
following tMCAO (Fig. 3.2A). Six hours after tMCAO (30 min occlusion), mice were perfused 
and isolated brains were divided into ipsilateral and contralateral hemispheres, and each 
hemisphere was analyzed separately for Evans blue extravasation. LPS significantly increased 
Evans blue extravasation in the ipsilateral hemisphere after tMCAO compared to control mice 
(Fig. 3.2B), indicating that LPS enhances cerebrovascular permeability after stroke.  
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LPS increases neutrophil infiltration into the injured brain in stroke 
Stroke and acute infections elicit inflammatory responses in the injured brain that are mediated 
by multiple factors. Neutrophils are among the first peripheral cells to infiltrate ischemic brain 
tissue within 30 minutes to a few hours after focal cerebral ischemia, and neutrophil infiltration 
is believed to contribute to acute phase damage in stroke (Gee et al., 2007). To assess brain 
leukocyte invasion, we measured neutrophils in brain and peripheral tissues by flow cytometry. 
Neutrophil accumulation in the ipsilateral and contralateral brain hemispheres was significantly 
greater in the LPS group compared to saline control (n = 5, P < 0.05) at 6 hours tMCAO post 
reperfusion (Fig. 3.2C). Concurrently, fewer neutrophils and greater lymphocytes were detected 
in the peripheral blood and spleen but monocytes did not differ between vehicle and LPS treated 
mice (supplemental Figure 3.1 A, C). The neutrophil to lymphocyte ratio (NLR) was 
significantly decreased in the blood (n = 5, P = 0.02), and spleen (n = 5, P = 0.004) of LPS-
treated mice (supplemental Figure 3.1 B, D). tMCAO mice with LPS exhibited worsened 
neurological score at all end point experiments (P = 0.0005, Fig. 3.2D), and mortality was higher 
in LPS versus saline tMCAO mice (4/23 vs. 0/18, respectively). Although neutrophil 
accumulation in the CNS is complex, these data are consistent with the LPS increased BBB 
permeability after tMCAO.  
 
LPS impairs mitochondrial oxidative phosphorylation in CVECs 
To determine if the LPS effects in stroke are due to direct effects on cerebrovascular endothelial 
cells, we employed a cultured cerebrovascular endothelial cell (cCVEC) model. 
Immunohistochemical staining showed that CD31 (an endothelial cell marker) and TLR4 (a LPS 
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receptor) colocalize in the brain vasculature (supplemental Figure 3.2 A), closely resembling the 
expression of CD31 and TLR4 on cCVECs (supplemental Figure 3.2 B). This indicates that 
cCVECs have critical components for an in vitro model to investigate LPS effects on 
cerebrovascular endothelial cells. 
The brain has a high energy demand and elevated mitochondrial content resulting in it being 
vulnerable to reductions in oxidative phosphorylation.  Given the expression of TLR4 on the 
brain vascular endothelial cells, we determined if LPS would directly affect oxidative 
phosphorylation and mitochondrial capacity in CVECs. Using Mitotracker Red for visualization 
of mitochondria, we detected MyD88, an adaptor protein involved in TLR4 signaling,(Gay et al., 
2014) broadly distributed but also colocalized with mitochondria in cCVECs (Fig. 3.3A), 
suggesting that LPS-induced signaling pathways are linked to mitochondria. To directly evaluate 
the mitochondrial function in cCVECs affected by LPS, a bioenergetic assay was used to 
examine cellular energetic oxygen consumption rates (OCR). Basal OCR did not significantly 
differ in cCVECs challenged by LPS for 24 hours, but maximal respiration and spare capacity 
were significantly reduced in cCVECs cultured with 0.1-100 µg/ml LPS (Fig. 3.3B & 
supplemental Figure 3.3 A). Similarly, in primary cerebrovascular endothelial cells (pCVECs), 
an LPS challenge for 24 hours resulted in a decrease in maximal respiration and spare capacity at 
100 μg/ml (Fig. 3.3C & supplemental Figure 3.3B).  However, reduced oxidative 
phosphorylation was not associated with cell death or cell viability in cCVECs or pCVECs, as 
evidenced by PI staining (supplemental Figure 3.4 A&B), calcein AM staining (supplemental 
Figure 3.4 C&D) for 24 hours in the exception of high dose of LPS (100 μg/ml). In view of the 
LPS effects on mitochondrial respiration, respiratory chain complex I proteins (NADH 
dehydrogenase ubiquinone subunits: NDUFAF1, NDUFS2 and NDUFA2), complex II protein 
(Succinate dehydrogenase, SDH), complex III protein (cytochrome c, Cyc), and complex IV 
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protein (Cytochrome c oxidase, COX IV) were examined after a 1 μg/ml LPS challenge for 48 
hours, and flow cytometry confirmed that LPS decreases the expression of complex I (NDUFS2 
and NDUFA2), complex III (Cyc) and complex IV (COX IV) (Fig. 3.3D) proteins. Together 
these results strongly suggest that oxidative phosphorylation of CVECs is compromised with 
LPS exposure, and this effect does not induce endothelial cell death. As such, we asked if 
mitochondrial activity affects endothelial cell function.  
 
Impaired mitochondria disrupt CVEC tight junction and increase BBB permeability  
It is known that LPS impairs the BBB permeability both in vitro and in vivo at doses which are 
thought to be caused by inflammatory mediators such as cytokines, (Banks and Erickson, 2010) 
but little is known about the role of mitochondria in BBB integrity. Using a pharmacological 
strategy to manipulate mitochondrial respiration, we first demonstrated that inhibition of 
respiratory chain complex I with rotenone (Fig. 3.4A), uncoupling of electron flow from ATP 
production with FCCP (Fig. 3.4B), or inhibition of complex V with oligomycin (Fig. 3.4C) 
rapidly increased FITC-dextran 70 permeability in a cCVEC monolayer transwell system in 
vitro. Immunocytochemical analysis revealed that the normally well-defined, linear cell-cell 
junctions were disrupted when oxidative phosphorylation was inhibited by mitochondrial 
inhibitors (Fig. 3.4D). Both increased permeability and cell-cell junction disruption due to 
inhibition of oxidative phosphorylation occurred in the absence of cell death as evidenced by PI 
staining (supplemental Figure 3.5 A) and calcein AM staining (supplemental Figure 3.5 B).  
These data suggest for the first time that mitochondria play a key role in maintaining BBB 
integrity in vitro. 
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To determine if inhibition of mitochondria affects the BBB permeability in vivo, we developed 
an epidural application model for CNS drug administration in mice (Fig. 3.5A-D). This model 
permits local drug delivery without traumatic brain injury (Fig. 3.5C), thus allowing assessment 
of BBB permeability. Rotenone (2µl, 2mg/ml dissolved in saline) was applied to the epidural 
surface, and BBB permeability was evaluated by Evans blue quantification after 6 hours. Mice 
treated with rotenone showed significantly higher Evans blue extravasation than vehicle controls 
(Fig. 3.5D). These data support the hypothesis that mitochondria are critical for the regulation of 
cerebrovascular permeability in vivo. 
 
Inhibition of mitochondrial function worsens stroke severity in mice 
If inhibition of mitochondrial function increases BBB permeability, the same perturbation would 
be expected to affect infarct size and stroke severity. When we treated mice with rotenone prior 
to tMCAO (Fig. 3.6A), increased BBB permeability (Fig. 3.6B) and infarct volumes (Fig. 3.6C), 
and worsened neurological deficits (Fig. 3.6D) were observed. Thus, the LPS-induced 
exacerbation of stroke outcome most likely is due to the deleterious effect of mitochondrial 
inhibition.  
 
3.5. Discussion  
Acute systemic infection is a risk factor and/or trigger for human stroke (Grau et al., 1995b; 
Grau et al., 1995a) and is associated with worsened clinical outcome (Palasik et al., 2005). 
Although much is known about the factors that worsen stroke severity in clinical subjects and 
experimental stroke models, less is understood about their mechanisms. Our data are the first to 
demonstrate that a bacterial infection mimic acts with ischemic challenge to markedly 
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exacerbate stroke damage via a mitochondrial-dependent mechanism. This new finding could 
also provide an explanation for the association of infections with severity of brain damage and 
BBB dysfunction from stroke: the induction of hypometabolism in cerebrovascular endothelial 
cell mitochondria.  
Mitochondrial dysfunction is increasingly recognized as an accomplice in vascular diseases and 
ischemic stroke. More recently, it has been shown that components of the TLR4 signaling 
pathways, MyD88 and TRAF6, are linked with mitochondria and affect oxidative 
phosphorylation (Kim et al., 2007). The expression of MyD88 in mitochondria of endothelial 
cells (Fig. 3.3A) supports that mitochondrial function can be affected by LPS (Fig. 3.3B&C). It 
is notable that no significant effect of LPS is seen on cCVEC basal oxygen consumption and 
ATP-linked oxygen consumption upon treatment with oligomycin (Fig. 3.3B & supplemental 
Figure 3.3), indicating that LPS does not significantly change basal oxygen demand in 
mitochondria after 24 hours of treatment with LPS. However, the loss of maximal respiration 
and spare capacity (Fig. 3.3B & supplemental Figure 3.3) demonstrates that mitochondrial 
capacity is reduced by LPS and thus the effects exacerbate the mitochondrial impairment by 
ischemia.  Cellular respiration, mitochondrial biogenesis and function, require coordinated 
expression of proteins encoded by nuclear and mitochondrial genes including mitochondrial 
complex I-IV. The reduced expression of respiratory chain complex I, III and IV proteins in 
cCVECs by LPS provides further evidence that LPS compromises the endothelial mitochondria 
function (Fig. 3.3D). 
 
The 30 minute tMCAO model mimics a mild ischemic event that results in a small infarct (Fig. 
3.1C) and does not cause visible BBB disruption at 6 hours reperfusion (Fig. 3.2B).  The 
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bacterial infection mimic challenge prior to tMCAO increased BBB permeability (Fig. 3.2B) and 
exacerbated infarct volume (Fig. 3.1C). There are inconsistent data for LPS- or cytokine-induced 
BBB dysfunction (Banks and Erickson, 2010) that may be due to complex mechanisms.  McColl 
et al. (2007) demonstrated an interleukin-1-dependent mechanism of stroke exacerbation using 
the same LPS-tMCAO model.  Others have demonstrated that LPS alters transporters or 
enzymes involved in BBB maintenance (Banks et al., 2008). Our observation that 
pharmacological inhibition of mitochondria disrupts BBB integrity and increases BBB 
permeability in vitro (Fig. 3.4) and in vivo (Fig. 3.5) strengthens the argument that BBB 
permeability is increased by LPS after stroke (Fig. 3.2) through a direct mitochondrial 
mechanism resulting in a larger infarct volume and worsening neurological deficit.  
 
Increased BBB permeability, is positively correlated with massive vasogenic and cytotoxic 
edema post-stroke (Taheri et al., 2009; Yang and Rosenberg, 2011) and elevated neutrophils in 
the ischemic area that contribute to infarct expansion (Bektas et al., 2010) and poor clinical 
outcome (Warach and Latour, 2004). Our observation of neutropenia and low NLR may be a 
consequence of BBB damage that causes rapid migration of neutrophils into damaged tissue. 
Brain infiltration of neutrophils could also account for secondary lesion growth and increased 
infarct size in the ischemic brain as seen with LPS treatment (Fig. 3.1C).  These data may 
provide translational evidence that neutropenia and low NLR may predict severe stroke.  
 
We observed that LPS-induced inhibition of mitochondria exacerbates infarct volume and opens 
BBB in tMCAO mice (Fig. 3.1&3.2), but that mitochondria inhibition in cCVECs and pCVECs 
does not affect cell viability in 24 hours (supplemental Figure 3.4). This suggests that the 
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functional impairment of endothelial mitochondria by LPS may be reversible and an effective 
intervention could be designed to prevent/restore BBB during strokes. However, our data also 
indicated that a high dose of LPS (100 μg/ml) induced cell death and reduced cell viability in 
cCVECs (supplemental Figure 3.4), and extension of LPS exposure for 48 hours induced cell 
death in both cCVECs and pCVECs (supplemental Figure 3.4 A-D). Therefore, the effective 
mitochondrial directed intervention may be limited by the severity or the length of the infectious 
exposure to rescue BBB damage.  
 
Leukocytosis, and cytokine and chemokine storm are features of the acute-phase reaction in 
systemic infections and in acute stroke. It is becoming increasingly apparent that inflammation 
can disturb cell energy metabolism.  Our recent study found that neuronal mitochondrial 
function was rapidly and profoundly decreased by TNF-α resulting in neuronal cell death (Doll 
et al., 2015a). Another study demonstrated that TNF-α elevated oxygen consumption rate in 
endothelial cells (Drabarek et al., 2012). The present study did not address the complex LPS-
induced effects on mitochondria, however, our novel findings refreshed the traditional idea of 
infection-inflammation responses and provided a new explanation for the LPS effects on BBB 
dysfunction: a direct mitochondrial-dependent mechanism. 
 
The application of rotenone on the epidural surface argues that its effect on BBB opening is by 
compromised mitochondria in vascular endothelial cells (Fig. 3.5). Rotenone exposure is 
associated with clinical features of parkinsonism in humans (Tanner et al., 2011), and broadly 
used to induce PD like-symptoms in animal models (Chesselet and Richter, 2011) as well. This 
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suggests that the mitochondrial-dependent BBB opening may not only involve in the progress of 
stroke but also other neurodegenerative disorders such as PD and AD. 
 
In summary, the present study describes a previously unknown mechanism of infection-induced 
direct mitochondrial dysfunction in cerebrovascular endothelial cells, which compromises BBB 
permeability and exacerbates acute stroke outcomes. Moreover, our observations argue that 
maintenance of mitochondrial function is critical to the integrity of the BBB. The data also 
suggest a translational significance: maintenance of brain endothelial cell mitochondrial function 
can improve the acute outcome of stroke and perhaps other neurodegenerative diseases.  
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Figure Legends: 
Fig. 3.1. LPS exacerbates stroke infarct volume in mice. (A) Scheme depicting the 
experimental design. LPS (100 µg/kg, i.p.) or vehicle (saline, i.p.) was administered 30 min prior 
to right transient middle cerebral artery occlusion (tMCAO; 30 min) and 48 hour reperfusion 
was performed. (B) Infarct volumes were measured at 48 hours after ischemia induction. 
Representative TTC-stained coronal sections used to analyze infarction of mice treated with 
vehicle vs. LPS. (C) Mice treated with LPS had significantly larger infarct volume than vehicle 
group in cortex, striatum and total hemisphere. Mean ± S.D.; n = 7 per group; Student’s t test. *, 
P < 0.05; **, P < 0.01. 
Fig. 3.2. LPS increases early BBB leakage and infiltration of neutrophils into the brain of 
stroke mice. (A) Scheme of experimental design and workflow. LPS (100 µg/kg, i.p.) or vehicle 
(saline, i.p.) was administered 30 min prior to right tMCAO (30 min occlusion) and 6 hour 
reperfusion was performed. (B) Evans blue accumulation was visible in the brain of LPS pre-
treated stroke mice (Red arrows) and quantification of Evans Blue extravasation (µg/g brain 
tissue) in contralateral (left) and ipsilateral (right) hemispheres. Vehicle, n = 6; LPS, n = 7. (C) 
Representative FACS data for individual hemispheres from mice treated with vehicle vs. LPS 
after 30 min tMCAO plus 6 hours reperfusion, and statistical analysis of infiltrated PMNs in the 
contralateral (left) and ipsilateral (right) hemispheres measured by FACS.  N = 5 per group. (D) 
Neurological score at combined two end points (6 hours and 48 hours) after tMCAO. Vehicle, n 
= 18, LPS, n = 23. Data are expressed as mean ± S.D.; One-way ANOVA followed by post-hoc 
Tukey’s test was used for multiple group comparison and Student’s t test was used for two group 
statistical analysis. (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001.) 
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Fig. 3.3. LPS reduces mitochondrial function in cultured and primary cerebrovascular 
endothelial cells. (A) Immunofluorescence staining of mitochondrial (MitoTracker, purple) co-
stained with MyD88 (green), suggests that the MyD88 expresses on mitochondria of cultured 
cerebral vascular endothelial cells (cCVECs). Nuclei were stained with DAPI (blue). Results are 
representative from four independent experiments. Images were taken under 63× objective. 
Scale bars = 10 μm. (B) Bioenergetics functional assay in cCVECs exposed to various 
concentration of LPS compared to vehicle control for 24 hours. Basal respiration, ATP 
production, maximal respiration, and spare capacity were calculated from the assay presented in 
supplementary Figure 3.3 A. Results are representative from four independent experiments. N = 
4 per group; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 vs. vehicle group. One way 
ANOVA followed by post-hoc Tukey’s test was used for data analysis. (C) Bioenergetics 
functional assay in pCVECs exposed to various concentration of LPS compared to vehicle 
control for 24 hours. Basal respiration, ATP production, maximal respiration, and spare capacity 
were calculated from the assay presented in supplementary Figure 3.3 B. Results are 
representative from four independent experiments. N = 4 per group; *, P < 0.05 vs. vehicle 
group. One way ANOVA followed by post-hoc Tukey’s test was used for data analysis. (D) 
Analysis of mitochondrial specific proteins for complex I proteins (NDUFAF1, NDUFS2, 
NDUFA2), complex II protein (succinate dehydrogenase, SDH), complex III protein 
(cytochrome c, Cyc), and complex IV protein (cytochrome c oxidase, cox IV) in cCVECs after a 
1 μg/ml LPS challenge for 48 hours.  Flow cytometry confirmed that LPS decreases the 
expression of complex I (NDUFS2 and NDUFA2), complex III (cytochrome c) and complex IV 
(cox IV) proteins. Results are representative from three independent experiments. N = 3 per 
group; *, P < 0.05; **, P < 0.01; ****, P < 0.0001 vs. vehicle group. Student’s t test was used 
for data analysis. 
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Fig. 3.4. Pharmacological inhibition of mitochondria increases BBB permeability in vitro. 
FITC-Dextran-70 permeability after addition of 20 µM rotenone (A), 20 µM FCCP (B) and 20 
µM oligomycin (C) vs. vehicle to cultured cerebrovascular endothelial cells (cCVECs). Data are 
presented as both real-time rate of permeability (Two-way ANOVA followed by post-hoc 
Dunnett's test) and calculated apparent permeability coefficient (Papp, Student t-test). N = 3 per 
group. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (D) Confocal fluorescence images of 
cCVEC confluent monolayers after treatment with 20 µM rotenone, 20 µM FCCP and 20 µM 
oligomycin vs. vehicle for 2 hours. The immunohistochemistry staining of ZO-1 (red) was 
performed for tight junctions. Nuclei were stained with DAPI (blue). Mitochondrial inhibitors 
apparently disrupted tight junctions and resulted in gaps between cells (white arrows).  
Fig. 3.5. Pharmacological inhibition of mitochondria increases BBB permeability in vivo. 
(A) Graph depicting the epidural application (EA) model. (B) Exposure of epidural membrane: 
vessels were visible under surgical microscope. (C) TTC staining in the EA model showing no 
brain injury. (D) Evans blue accumulation was visible in the brain of rotenone applied mice (red 
arrows) in EA model and quantitative analysis of Evans blue extravasation (µg/g brain tissue) in 
individual brain. N = 5 per group; One-way ANOVA followed by post-hoc Tukey’s test. Data 
are expressed as mean ± S.D.; **, P < 0.01. 
Fig. 3.6. Impairment of mitochondria function exacerbates stroke outcomes. (A) Scheme of 
experimental design and workflow. Rotenone (1mg/kg, i.p.) or vehicle (saline, i.p.) was 
administered 30 min prior to right tMCAO (60 min occlusion), BBB permeability was evaluated 
at 6 hour reperfusion and infarct volume was measured at 24 hour reperfusion. (B) 
Representative brain coronal sections for Evans blue accumulation and quantitative analysis of 
Evans Blue extravasation (µg/g brain tissue) in contralateral (left) and ipsilateral (right) 
hemispheres. Vehicle, n = 4; Rotenone, n = 4. One-way Data are analyzed with ANOVA 
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followed by post-hoc Tukey’s test (*, P < 0.05). (C) Representative TTC-stained coronal 
sections used to analyze infarct of tMCAO mice and quantitative analysis of infarct volumes. 
Mice treated with rotenone had significant larger infarct volume than vehicle group, in cortex, 
striatum, and total hemisphere. Rotenone (1 mg/kg, i.p.) or vehicle (saline, i.p.) was 
administered 30 min prior to right tMCAO (1 hour occlusion) and 24 hour reperfusion was 
performed. Vehicle, n = 8; Rotenone, n = 8. Data are analyzed with Student’s t tests (**, P < 
0.01; ***, P <0.001; ****, P < 0.0001.). (D) Rotenone worsened neurological deficits at 6 and 
24 hours after tMCAO. Vehicle, n = 12; Rotenone, n = 12. Data are analyzed with Student’s t 
















































































































Supplemental Materials and Methods: 
 
Cell viability assay 
We performed the cell viability assay simultaneously with the oxygen consumption assay. We 
seeded cells in 96 black well plates and treated with LPS. We added PI (2 µg/ml) to evaluate 
cell death on plate reader (Ex. 535 nm and Em. 617 nm), washed with PBS, added Calcein AM 




To obtain brain samples for immunohistochemistry assays, animals were anesthetized with 
isofluorane and perfused with PBS followed by 10% formalin PBS. Brains were removed, post- 
fixed overnight in 10% formalin PBS at 4°C, cryoprotected in graded sucrose solutions, and 
embedded in Tissue-Tek OCT (VWR Scientific). Coronal sections (20 μm) were cut through, 
blocked with 5% goat serum staining buffer and stained with rabbit anti-mouse TLR4 (1:100, 
Abcam, Cambridge, Massachusetts) and rat anti-mouse CD31 (1:200, Abcam) overnight, and 
then washed with PBS and stained with goat-anti-rabbit-FITC and goat-anti-rat-PE antibodies 
(Life technologies, Grand Island, New York) for 2 hours. The sections were further washed 
with PBS and mounted on glass slides using prolong gold anti-fade reagent (Life  
technologies). 
To perform the immunohistochemistry staining on bEnd.3 cells, the cells were cultured on 
cover slips and fixed with 4% cold paraformaldehyde (PFA, Polysciences, Inc.) followed by 
blocking, staining, washing and mounting, as outlined above. The slides or sections were 
photographed with confocal LSM 510 microscope Zeiss (Zeiss, Oberkochen, Germany) using 
software ZEN  2012. 
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Statistical Analysis 
Statistical analysis was performed with Prism 5 software (Graphpad software, La Jolla, 
California). Differences between groups were analyzed by the unpaired Student’s t-test or one 






Supplemental Figure 3.1. LPS significantly decreases neutrophils and increases 
lymphocytes in peripheral blood and spleen after stroke. Analysis of neutrophils, 
monocytes and lymphocytes in blood (A) and spleen (C). Representative FACS data of blood 
and spleen showing percentage of Gr1+ polymorphonuclear neutrophils (PMNs), CD11b+Gr1- 
monocytes, and CD11b- Gr1- lymphocytes gated in CD45+ white blood cells (WBCs). 
Neutrophil-to-lymphocyte ratio (NLR) in blood (B) and spleen (D). Mice pre-treated with LPS 
had significantly fewer neutrophils but more lymphocytes in the blood and spleen than vehicle 
group after 30 min tMCAO and 6 hours reperfusion. Data are expressed as mean ± S.D.; n = 5 






Supplemental Figure 3.2. LPS receptor, TLR4, is expressed by endothelial cells in brain 
tissue and in culture. (A) Sections from normal mouse brains stained with antibodies to TLR4 
(purple) show TLR4 staining in association with CD31 (green), a specific marker for 
endothelial cells. (B) Micrographs showing TLR4 (purple) expression in cultured 
cerebrovascular endothelial cells (CCVECs, bEnd.3 cell line). Nuclei were stained with DAPI 
(blue). Results are representative from four independent experiments. Images were taken under 






Supplemental Figure 3.3. The raw data of oxygen consumption rate determined by the 
Seahorse XF96e analyzer. (A) cultured cerebrovascular endothelial cells (cCVECs, bEnd.3 
cell line) were incubated with various concentrations of LPS for 24 hours then oxygen 
consumption rate (OCR) was determined by the Seahorse XF96e analyzer. (B) Primary 
cerebrovascular endothelial cells (pCVECs, originally from adult mouse brain) were incubated 
with various concentrations of LPS for 24 hours then OCR was determined by the Seahorse 
XF96e analyzer. The mitochondrial inhibitors: oligomycin, FCCP, and rotenone plus antimycin 
A were sequentially injected after measurement points 3, 6, and 9 as indicated. Data are 





Supplemental Figure 3.4. LPS and cell viability in cultured cerebrovascular endothelial 
cells and primary cerebrovascular endothelial cells. Evaluation of LPS on cell death by 
propidium iodide (PI) staining. cCVECs (A) or pCVECs (B) were cultured with LPS (0.01 - 
100 µg/ml) for 24 and 48 hours then stained with PI (2 µg/ml). A microplate reader was 
immediately used to determine the mean fluorescent intensity of PI staining. Effect of LPS on 
cell viability of cCVECs (C) or pCVECs (D) by calcein-AM staining. After PI staining, cells 
were washed with PBS and incubated with calcein-AM (5 µM) for 30 minutes. A microplate 
reader was used to determine the mean fluorescent intensity of Calcein AM staining. Data are 
presented as mean ± S.D., analyzed by One-way ANOVA followed by post-hoc Tukey’s test. 
LPS at 100 µg/ml significantly induced cell death and reduced cell viability in cCVECs after 24 
hours culture.  *, P<0.05, **, P < 0.01; 







Supplemental Figure 3.5. Mitochondria inhibitors and cell viability in cultured 
cerebrovascular endothelial cells at 2 hours. (A) Evaluation of mitochondria inhibitors: 
rotenone, FCCP and oligomycin on cell death by propidium iodide (PI) staining in cCVECs. 
Confluent cCVEC monolayer were treated with rotenone, FCCP or ologomycin (5 - 80 µM) for 
2 hours then stained with PI (2 µg/ml). A microplate reader was immediately used to determine 
the mean fluorescent intensity of PI staining. (B) Effects of mitochondria inhibitors on cell 
viability by calcein-AM staining. After PI staining, cells were washed with PBS and incubated 
with calcein- AM (5 µM) for 30 minutes. Mean fluorescence intensity was determined using a 
microplate reader. Data are presented as mean ± S.D., analyzed by One-way ANOVA followed 
by post-hoc Tukey’s test. Rotenone at 80 µM significantly reduced cell viability after 2 hours 
treatment. Data are presented as mean ± S.D., analyzed by One-way ANOVA followed by post-
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Background:  A third of ischemic stroke cases have no traditional underlying causes such as 
hypertension, diabetes, atherosclerosis, obesity, or age.  Moreover, thirty to forty percent of 
strokes occur during or acutely after an active infection and the incidence of stroke increases 
during flu season.  We and others have shown that the combination of a minor bacterial infection 
mimic, 100 μg/kg of lipopolysaccharide (LPS) prior to a minor stroke - 30 minute transient 
middle cerebral artery occlusion (tMCAO) - exacerbates infarct volume in a mouse model.  
Thus, experimental and epidemiological data strongly suggest that infection and/or inflammation 
play a role in stroke occurrence and severity.  However, to date, long-term outcomes of stroke 
during an active infection has not been studied.   
Methods:  3-4 month old C57Bl6/J mice were treated with saline or LPS 30 minutes prior to a 
30 minute tMCAO or sham surgery.  A behavioral battery was administered to assess health 
status/sickness behavior, neurological deficits, motor, cognitive, and affective behaviors.   
Results:  We show for the first time that exposure to a low dose of LPS prior to a mild stroke 
significantly worsens neurological deficits and sickness scores.  Motor, cognitive, and affective 
behaviors were assessed post-stroke and while stroke significantly affected motor behavior on 
rotarod, LPS did not increase the motor deficits.  We did not observe any effects of stroke or LPS 
on cognitive and affective behaviors.   
Conclusions:  Our observations of the association between infection, stroke, and worse sickness 
and neurological outcomes identify 1) a clinical need to aggressively treat infections in people 
with risk factors for stroke and 2) the need to understand the mechanism(s) of the association 





Stroke is the 5th leading cause of death in the United States and the leading cause of disability 
(Lackland et al., 2014).  Numerous risk factors such as diabetes, hypertension, and 
atherosclerosis have been recognized to increase susceptibility to stroke; however, the 
epidemiology of ischemic stroke is not sufficiently explained by the prevalence of these 
cerebrovascular risk factors (Grau et al., 1995b).  In at least a third of ischemic stroke cases, the 
patients lack traditional risk factors and have no apparent cause.  The presence of systemic 
infection could be an important mediating risk factor.  Indeed, thirty to forty percent of strokes 
occur during or acutely after an infection (Grau et al., 1995b) suggest an association between 
systemic infection and stroke.  Although infection has been implicated in increasing 
susceptibility to stroke, few studies have examined how an infection prior to stroke affects 
outcome.  McColl et al. (2007) and Doll et al. (2015c) found that administering 
lipopolysaccharide (LPS) 30 minutes prior to transient middle cerebral artery occlusion 
(tMCAO) resulted in an increased infarct volume.  We have shown that a mechanism by which 
lipopolysaccharide (LPS) exacerbates stroke damage involves an increase in blood brain barrier 
(BBB) damage through mitochondrial dysfunction (Doll et al., 2015c) and others have suggested 
a cytokine-dependent mechanism (McColl et al., 2007).  Together, these findings suggest an 
association between systemic infection and stroke.   
 
While it is clear that bacterial infection prior to stroke can affect acute stroke damage (McColl et 
al., 2007; Doll et al., 2015b), to our knowledge no studies have examined the long-term effects 
of a bacterial infection mimic on behavioral outcomes.  We hypothesized that LPS administered 
prior to stroke would exacerbate the motor, cognitive, and affective behavioral deficits post-
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stroke.  To test our hypothesis, we used an animal model of mild infection and mild stroke 
developed by McColl et al. (2007), then assessed sickness behavior, neurological deficits, 
locomotor, cognitive, and affective behaviors to determine if a bacterial infection can exacerbate 




C57/BL6J male mice (3-4 months old, 25-30g, Jackson Laboratories) were used for all studies. 
All procedures were conducted according to criteria approved by the Institutional Animal Care 
and Use Committees at the West Virginia University.  
 
Randomization and blinding of the animal experiments 
To assign groups (Vehicle Sham, LPS Sham, Vehicle Stroke, LPS Stroke), we numbered the 
animals and applied a simple randomization by using excel-generated random numbers. To avoid 
biases, we also assured that sham and stroke surgeries along with the different treatments (LPS 
or vehicle) were performed on the same day. The experimenters were blinded to the pre-
treatments and data analysis. 
 
Drug administration 
LPS (Escherichia coli 055:B5, 100 μg/kg, Sigma) dissolved in saline (B. Braun Medical Inc. 
Irvine, California) was administered via an intraperitoneal injection 30 min prior to tMCAO or 
sham surgery. An equal volume of saline was administered to vehicle treated mice.  
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Ischemic model and sham surgery 
We performed focal cerebral ischemia for 30 min by occlusion of the right middle cerebral artery 
with a 6.0 monofilament suture (Doccol, Sharon, Massachusetts). All surgical anesthesia was 
induced with 4-5% isoflurane until the animal showed no response to a toe pinch, and was 
maintained with 1-2% isoflurane via face-mask in O2-enriched air. We used laser Doppler 
flowmetry (Moor instruments, United Kingdom) to detect regional cerebral blood flow and 
confirm a successful occlusion (>70% decrease in flow). Rectal body temperature was 
maintained at 37 ± 0.5 °C during surgery. One cohort of mice was euthanized at 48 hours post-
stroke to assess infarct area, and a separate cohort was euthanized at the end of the behavioral 
battery.  
 
Analysis of brain infarct area-Cohort 1 
In one cohort, a total of 28 mice (N=7/group) were euthanized with isoflurane 48 hours post-
ischemia. We removed the brains and cut 2 mm coronal sections with a mouse brain matrix. We 
stained the sections with 2% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma, Saint Louis, 
Missouri) in phosphate buffer solution (PBS) at 37°C for 30 minutes then fixed the tissue in 10% 
formalin phosphate buffer for digital photograph. We analyzed the digitized image of each brain 
section using computerized image analysis software (ImageJ, NIH) in a double-blinded manner. 






Behavioral Test Battery-Cohort 2 
In another cohort, a total of 40 mice (Vehicle Sham = 10; LPS Sham = 10; Vehicle Stroke = 10; 
LPS Stroke = 10) underwent behavioral testing. Two animals were excluded from the LPS stroke 
group; one due to post-mortem evidence of cerebral hemorrhage, and a second due to a surgery 
complication.  The animal excluded due to a surgery complication was replaced resulting in an n 
= 9 for the LPS stroke group.  The animals were treated and assessed in two cohorts with n = 5 in 
each group for each cohort.  We selected the following behavioral tests to assess a range of 
affective, locomotor, and cognitive abilities and to identify and control for potential locomotor, 
visual, or motivational alterations effected by stroke and bacterial infection prior to stroke. 
Figure 4.1 depicts the time-course of behavioral testing.   All animals underwent the entire test 
battery with the exception of Morris water maze.  The first cohort showed no significant effects 
or trends toward a treatment or surgery effect on this test; thus, we did not subject the second 
cohort of animals to Morris water maze testing.  However, the timing post-stroke of the other 
behavioral assessments were maintained constant across cohorts.  All testing was completed 
during the light cycle (08:00-15:00) by the same experimenter, who was blind to treatment group 
status. Central air conditioning fans provided white noise in the testing room. Between each 
animal, the behavior apparatus was cleaned of debris with Virkon and, when appropriate (Open 
Field, Elevated Plus Maze), 50% ethanol.   
 
Health and Sickness Behavior Screen 
Overall health and sickness behavior was assesses using an objective 20 point screen developed 
in our laboratory.  The health screen was administered daily by the same experimenter who was 
blind to treatment group status.  The screen encompasses seven physical domains designed to 
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provide insight into the global physical health of an animal. The screen was designed to be rapid 
and easy to administer, to be minimally invasive, and to ensure consistency in scoring across the 
post-stroke recovery period. To assess health status and sickness behavior, the animal was 
observed in its home cage for general appearance, posture, respiration, and spontaneous 
locomotion/social interaction.  Body condition (emaciation and hydration) was assessed by the 
pinch test.  Body temperature and body weight were also measured (see supplemental Table 4.1 
for scoring criteria).  The screen was administered twice prior to tMCAO and each day post-
tMCAO for 7 days between 0800 and 0930.   
 
Modified Neurological Severity Score (mNSS) 
The mNSS, adapted from Chen et al. (2005), assessed neurologic function on a scale of 0 to 12 
with 0 being normal and 12 being maximal deficit (see supplemental Table 4.2 for scoring 
criteria).  The mNSS used here was composed of motor and balance tests; the reflex test was 
eliminated due to habituation of the mice after repeat testing.  mNSS scores were determined 
twice prior to tMCAO and each day post-tMCAO for 7 days between 0800 and 0930. 
 
Cylinder Test 
The cylinder test evaluates spontaneous forelimb use and asymmetries resulting from neural 
injury(Schaar et al., 2010).  The animal was placed in a transparent cylinder (12 cm wide, 19 cm 
tall) for 5 minutes and allowed to freely explore. Performance was video recorded for later 
assessment. The number of independent wall placements for the right and left forelimbs, in 
addition to placement of both forelimbs simultaneously, were recorded.  Cylinder test 
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performance was conducted twice prior to tMCAO to account for pre-operative handedness 
biases, as well as 1, 3, 5 and 7 days post-tMCAO.  
 
Open Field 
This task evaluates locomotor activity and emotional reactivity (Denenberg, 1969). A white 
plastic box (60 cm x 60 cm x 15 cm) was placed upon a table. Five desk lamps (60 watt each) 
provided indirect illumination. At the start of the trial, each mouse was placed in arena at the 
midpoint of the South wall and received a 6 minutes session. Locomotor activity was recorded 
using Ethovision 8.5 (Noldus Information Technology, Wageningenm, Netherlands). For 
analysis, the box floor was divided into inner zone, middle frame, and perimeter zones. The 
dependent variables were fecal boli excreted, and distance moved (cm) in the arena as well as 
distance moved (cm) in each zone.  
 
Elevated Plus Maze 
This task assesses anxiety-like behavior in a novel environment, with mice spending less time in 
open arms considered ‘anxious’(Hogg, 1996). Two intersecting arm pairs were arranged in a 
‘plus’ configuration and elevated 60 cm from the floor. One arm pair, 58 cm long x 5 cm wide, 
was enclosed by walls 15 cm tall and the other arm pair remained open (no walls or edges). 
Room illumination consisted of ambient lighting. Each mouse was placed at the arm intersection 
point and allowed to freely explore for 5 minutes. The dependent variables were the frequency of 






This task confirms visual and motor competence for water maze testing (Engler-Chiurazzi et al., 
2012). A circular tub (140 cm in diameter) was filled with clear water. A white- and black-
colored platform with a white/black flag was positioned approximately 0.5 cm above the water 
surface in a fixed location within the pool. Blue curtains covered obvious extra maze cues. The 
drop-off location varied semi-randomly across trials. Each mouse had 90 sec to locate the 
platform, where it remained for 15 sec before being placed back into its heated cage. If an animal 
did not locate the platform within the allotted time limit, it was gently guided to the platform. 
Between animals, the maze was cleaned of debris and olfactory cues were disrupted using a 
fishnet. The inter-trial interval was approximately 12 min. Latency (sec) to reach the platform 
was the dependent measure.  
 
Morris Water Maze 
Acquisition: The Morris water maze tests hippocampal-dependent spatial reference memory 
(Morris et al., 1982), memory for information that remains consistent across time (Olton, 1979). 
A round tub (140 cm in diameter) was filled with room temperature water made opaque with 
non-toxic paint. Spatial cues (shelving, door, striped posters, etc) were indirectly lit. Briefly, the 
mouse was placed in the maze from any of four locations (North, South, East, or West) and had 
60 sec to locate a hidden platform submerged 1 cm, which remained in a fixed location 
(Northwest quadrant; NW). If an animal failed to locate the platform, it was gently guided to the 
platform. After 15 sec on the platform, the mouse was placed into its heated cage until the next 
trial. Between animals, the maze was cleaned of debris and olfactory cues. There was 
approximately a 15 min inter-trial interval between trials. A tracking system (Ethovision XT 8.5) 
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analyzed each mouse’s swim path.  Animals received 4 trials for 6 days. The dependent measure 
was swim distance (cm). Swim speed (cm/s) was assessed to determine possible locomotor 
differences. 
Probe Trial: To assess platform localization, on the 6th day of testing an additional probe trial 
was given (trial 5), whereby the platform was removed from the maze. Percent of total swim 
distance (cm) in the target NW quadrant (i.e., quadrant that once contained the platform) versus 
the opposite Southeast (SE) quadrant and frequency of platform zone crossings were the 
dependent measure (Stavnezer et al., 2002).  
Reversal: To assess cognitive flexibility/perseveration (D'Hooge and De Deyn, 2001), reversal 
learning was assessed the following day, whereby the platform was relocated to the SE quadrant. 
Animals received 4 trials for 2 days, with a 15 min delay between trials three and four. Trial 5 
was a probe trial on day 2. All testing procedures were identical to the Morris water maze 
acquisition and probe testing. 
 
Accelerating Rotarod 
This task assesses locomotor performance and coordination. A textured plastic horizontal rod (3 
cm in diameter) was mounted 14.5 cm above a pressure-sensitive base (Ugo Basile). 
Acceleration was set to 4-44 rpm in 300 sec (Jung et al., 2011). For a given trial, a mouse was 
placed on the rod and the motor and timer switch were activated. Acceleration continued until 
the mouse fell onto the padded base or until 300 sec had elapsed. Animals received 4 trials per 
session, with an inter-trial interval of 20 min, and two sessions per day, with an inter-session 




Modified Porsolt Forced Swim Test 
This test assesses depressive-like behavioral despair (Cryan et al., 2002). A plastic cylinder (19 
cm tall, 12 cm wide) was filled up to a height of 10.5 cm with 25 °C water. Each animal was 
tested for 6 minutes. Following each trial, the animal was removed, dried with paper towels, and 
warmed in cages heated with a heat pad. The water was changed after each trial. Behavior was 
video recorded and quantified by a blind observer who scored each animal as either engaging in 
1) active escape behaviors (swimming, climbing, and diving) or 2) immobility (floating or 
minimally moving). Behavior of each animal during the first 2 min was not included. Latency (s) 
to first immobility, total time (s) spent immobile, and number of fecal boli excreted were the 
dependent variables.  
 
Statistical Analysis 
Statistical analyses were performed with Statview. Differences between groups were analyzed by 
the unpaired Student’s t-test, two-way ANOVA or a repeated measure two-way ANOVA as 




Low dose bacterial infection mimic administered 30 minutes prior to a mild (30 minute) tMCAO 
increased cortical infarct area (p < 0.05) and caudate/putamen infarct area (p < 0.05) (Figure 
4.2).  We measured rectal temperature at 0, 6, 12, 18, 24, and 48 hours post-stroke to ensure that 
the increase in infarct volume was not due to an increase in temperature after stroke, and this 
data was reported in Doll et al. (2015c)  Stroke alone caused a modest decline in rectal 
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temperature, while LPS + stroke caused a marked hypothermia post-stroke (Doll et al., 2015c). 
These data indicate that the observed increase in infarct volume caused by the combination of 
LPS and tMCAO was not due to a febrile response. As such, we then conducted assessments in 
an additional cohort of mice for the effects of LPS on the behavioral outcomes of stroke.  
 
Modified Neurological Severity Score 
To assess functional neurological damage, the modified neurological severity score (mNSS) 
adapted from Chen et al. (2005) was administered for 7 days post-surgery.  Prior to surgery, the 
mNSS was administered to assess baseline biases, and animals in all 4 groups scored similarly.  
Overall there was a Day x Treatment (p = 0.0067) and Day x Surgery interaction (p < 0.0001).  
Upon visual inspection of the graph, the stroke and LPS effect diminished over time resulting in 
the effect of surgery or treatment being exacerbated in the acute recovery phase (days 1 – 3) 
(Figure 4.3), but in the sub-acute recovery phase (days 4 – 6), mNSS scores returned to baseline 
levels.  This rapid recovery after an insult in mice has been noted previously (Bouet et al., 2007; 
Freret et al., 2009).  Thus, we blocked the data by acute recovery phase (days 1 – 3) and sub-
acute recovery phase (days 4 – 6) to determine the effect of treatment, surgery, and their 
interaction on neurological deficits.     During the first three days post-surgery, there was an 
overall Treatment x Surgery interaction (p = 0.0454) indicating that LPS worsens neurological 
deficits post-stroke.  However, during the sub-acute recovery phase the Treatment x Surgery 






Health and Sickness Behavior Screen 
Prior to tMCAO (time point 0), the animals in all four groups had a health screen score of 0 
indicating that all animals were healthy animals at the time of treatment administration and/or 
stroke surgery (Figure 4.4).  Overall, there was a Day x Treatment (p < 0.005) and a Day x 
Surgery interaction (p < 0.0001).  Upon visual inspection of the graph, the surgery and treatment 
effects were diminished over time, similarly to the mNSS.  Thus, we blocked the data by acute 
recovery phase (days 1 – 3) and sub-acute recovery phase (days 4 – 6) to determine the effect of 
treatment, surgery, and the interaction on sickness behavior.  Overall there were no interactions 
between stroke and LPS during the acute or sub-acute recovery phase.  During both block of 
days there was a significant Surgery effect (p < 0.0001); however, only during the acute phase 
was there a significant Treatment effect (p < 0.0005).  By the sub-acute recovery, the Treatment 
effect diminished (p = 0.0842), but the Surgery effect remained (p < 0.0001).   
 
Motor Function 
To assess motor function, performance on the accelerating rotarod was assessed 11 ± 1 days 
post-surgery.  There was a significant stroke effect resulting in decreased motor function (p < 
0.005; Figure 4.5).  This effect of stroke surgery on motor function was not due to decreased 
locomotor activity because open field indicated no differences between the groups (Table 4.1).  
To assess forelimb functional asymmetries, the cylinder task was administered.  Before surgery 
(Day 0), there were no differences between groups on rearing (Figure 4.6) nor on left versus right 
forelimb placement (data not shown).  There was an overall Day x Surgery effect (p < 0.0001) 
post-surgery (Figure 4.6); thus, we further investigated the effect of surgery on each day.  There 
was a significant Surgery effect (p < 0.0005) on rearing on Day 1, indicating that animals that 
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had undergone stroke (regardless of drug treatment) were less active than animals who received 
sham surgery.  By day 3, the surgery effect diminished.  This finding of depressed locomotor 
behavior (as measured by overall number or rears) limits the interpretation of paw placement 
findings.   
 
Affective Behaviors 
Stroke nor LPS impacted general locomotor ability nor anxiety-like behavior in the open field 
(Table 4.1).  There were no significant group differences in distance moved in any zone during 
the 6 minute trial (Table 4.1).  Similarly, stroke nor LPS impacted anxiety-like behavior on the 
elevated plus maze.  There were no group differences in the number of open arm entries, number 
of closed arm entries, or the time (s) spent in the open arms (data not shown).  Moreover, neither 
stroke nor LPS impacted depressive-like behavior on the forced swim test.  There were no 
significant treatment effects on total time spent immobile, or latency to first immobility (data not 




Recent studies have indicated that both Helicobacter pylori (H. pylori) (Wang et al., 2012) and 
human cytomegalovirus (HCMV) (Huang et al., 2012) infections are associated with increased 
risk for ischemic stroke.   Moreover, having a respiratory tract infection increases the risk for an 
atherothrombotic ischemic event for up to 3 months (Zurru et al., 2009) and chronic bronchitis 
increases risk for stroke and transient ischemic attacks (TIA) (Grau et al., 2009).   Lastly, 
Grabska et al. (2011) conducted a retrospective chart review of 2066 ischemic stroke patients to 
assess the effect of pre-stroke and post-stroke infection on ischemic stroke severity and found 
that pre-stroke infection increased poor outcomes within the first 30 days but did not have effects 
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at 90 days on modified Rankin scores.  From a preclinical perspective, LPS has been shown to 
increase infarct volume when administered prior to MCAO in rodents (McColl et al., 2007; Doll 
et al., 2015c).  However, the long-term effects of stroke during an active infection have not been 
studied previously.  The present study shows for the first time that low dose LPS increases and 
prolongs sickness behavior and worsens neurological deficits post-stroke.    Thus, infection 
appears to both trigger and worsen severity of stroke. 
 
It is known that a severe stroke results in motor, cognitive, and affective behavioral deficits 
(Markgraf et al., 1994; Rogers et al., 1997; Gibson and Murphy, 2004; Winter et al., 2005; Bouet 
et al., 2007). Further, studies have shown that high doses of LPS causes motor, cognitive, and 
affective deficits (Dunn and Swiergiel, 2005; De Domenico et al., 2010; Hritcu et al., 2011; 
Painsipp et al., 2011; Tarr et al., 2011; Biesmans et al., 2013).  However, until the current study, 
the long-term functional outcomes of stroke in combination with an active infection had not been 
methodically assessed in the rodent model. We hypothesized that the LPS administered prior to 
stroke would exacerbate the motor, cognitive, and affective behavioral deficits post-stroke.  Our 
most robust effects of low dose LPS + mild stroke were on lesion volume, mNSS and sickness. 
The hypothermic response to LPS + stroke could be an adaptive protective response, because in 
other studies, we observed that maintenance of core body temperature following LPS + stroke 
resulted in profound sickness and death of mice (Doll et al., unpublished observations) and that 
acute post-stroke hypothermia is strongly associated with larger infarct size in mice (Heng et al., 
unpublished observations). The LPS + stroke effects on mNSS and sickness peaked at one day 
after stroke, then recovered over the 7-day observation period, indicating that acute behavioral 
response to LPS + stroke is transient, as has been previously reported for stroke alone in rodents 
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and humans (Schaar et al., 2010; Grabska et al., 2011).  We also showed that stroke, but not LPS 
treatment, affects balance and motor coordination during the accelerating rotarod task. As well, 
we did not observe effects of stroke, LPS, or their combination on open field, elevated plus maze 
or forced swim. Taken together, we demonstrate for the first time that an infection, present at the 
time of brain trauma (induced by MCAO) can exacerbate detrimental stroke outcomes, 
negatively impacting health and significantly prolonging recovery. 
 
Limitations of the present study are several. We did not observe some of the previously reported 
behavioral deficits that have been found following MCAO or LPS among rodents. This is most 
likely due to methodological differences between our work and previous studies including 1) the 
timing of post-manipulation assessments, 2) the severity of the model of brain insult used here, 
and 3) the low dose of LPS used in our study.  Indeed, it is well recognized that there are critical 
periods for detecting post-stroke deficits (Schaar et al., 2010). As well, many studies assessing 
functional outcomes following LPS assessed performance within hours of treatment 
administration. Thus, we may have not seen LPS + stroke effects in some behaviors due to the 
timing of assessment.  Also, severity of the stroke insult may have influenced our ability to 
detect functional deficits.   Our stroke was a 30 minute tMCAO, which is considered a minor 
insult, and caused a small infarct (Figure 2). The low dose of LPS used here, and thus the 
severity of the infection induced at the time of stroke also may explain why we did not observe 
substantial detrimental behavioral changes. Although others have shown that LPS results in 
motor, cognitive, and affective behavioral deficits, the doses used ranged from 0.3 – 10 mg/kg 
which are 3 – 100 times higher than the dose used in the present study.  Additionally, a few 
studies injected LPS multiple times before assessing behavior (Hritcu et al., 2011); thus, the 
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single, low LPS dose given in this study likely resulted in a minor bacterial infection mimic, and 
the chosen battery of functional assessments may have not been sensitive enough to detect a mild 
impairment at the time points at which they were administered.  Future studies should assess 
different doses of LPS and determine the time to assess different behavioral deficits.   
 
Furthermore, an increase prevalence of strokes occurs during flu season. Here, we utilized LPS, a 
bacterial infection mimic. However, it is not clear whether the exacerbation of post-stroke 
functional deficits by LPS found here extend to other types of infection. Thus, the assessment of 
the effects of a viral infection mimic prior to stroke on functional outcome is needed.   
This study was not designed to assess the mechanism(s) of the interaction between LPS and 
stroke, but rather to describe the consequences of this interaction on lesion volume, neurological 
deficits, sickness and behavioral outcomes. There are several potential mechanisms by which 
LPS could exacerbate stroke outcome. LPS itself is neurotoxic (Lehnardt et al., 2003), and 
increases levels of several neurotoxic cytokines, including TNFα (McColl et al., 2007). We have 
shown that TNFα causes neuronal loss by inhibition of mitochondrial oxidative phosphorylation 
(Doll et al., 2015a). Additionally, LPS compromised the blood-brain barrier (BBB) (Doll et al., 
2015c). As such, through either or both mechanisms, treatment with low doses of LPS may 
sensitize animals to the subsequent effects of a mild stroke and thereby worsen outcomes.  
Thus, we can conclude from this study that a minor bacterial infection mimic prior to a minor 
stroke results in increased infarct area, increased sickness behavior and worse neurological 
deficits resulting in delayed functional recovery.  Our observations of the association between 
infection, stroke, and worse sickness and neurological outcomes argues for the need to 
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aggressively treat infection in people with risk factors for stroke and the need to understand the 







































Table 4.1:  Stroke or LPS does not have an effect on locomotor ability in open field.  
Reported are means ± standard error of mean for total distance moved (cm), center duration 
(seconds), inner duration (seconds), and outer duration (seconds) during the open field task for 











Vehicle Sham 2295± 231  5 ± 2 15 ± 3 340 ± 5 
LPS Sham 2384 ± 208  5 ± 1 12 ± 3 343 ± 5 
Vehicle Stroke 2521 ± 257 5 ± 1 16 ± 5 339 ± 6 










































Figure 4.1:  Timeline schematic of treatment, surgery and behavioral testing.   
Figure 4.2:  LPS exacerbates infarct area.  Cortical and Caudate/Putamen infarct area.  A 
student’s t-test between control and treatment group showed a significant increase in cortical 
infarct area (p = 0.0488) and caudate/putamen infarct area (p = 0.0134).  Depicted are mean ± 
SEM for 7 mice/group. * p < 0.05 
Figure 4.3:  Stroke and Stroke + LPS exacerbate neurological deficits.  A two way repeated 
measures ANOVA showed a significant day by treatment (p = 0.0067) and day by surgery effect 
(p < 0.0001).  When blocking the data, day 1 – 3 (acute phase recovery) and day 4 – 6 (sub-acute 
phase recovery), there was a significant treatment by surgery interaction (0.0454) during the 
acute phase of recovery.  This significant treatment by surgery interaction was lost during the 
sub-acute phase of recovery. Depicted are mean ± SEM for 9 to 10 mice/group. When SEM is 
not shown, it is smaller than the symbol used to depict the mean.  * p < 0.05 
Figure 4.4:  Stroke induces sickness behavior.  A two way repeated measures ANOVA showed a 
significant day by treatment (p = 0.0006) and day by surgery effect (p < 0.0001).   When 
blocking the data, day 1 – 3 (acute phase recovery) and day 4 – 6 (sub-acute phase recovery, 
there was a significant day by surgery effect (p < 0.0001).  Depicted are mean ± SEM for 9 to 10 
mice/group. When SEM is not shown, it is smaller than the symbol used to depict the mean. ** p 
< 0.01; *** p < 0.001 
Figure 4.5:  Stroke increases motor dysfunction.  A two way repeated measures ANOVA showed 
a significant surgery effect (p = 0.0011).  Depicted are mean ± SEM for 9 to 10 mice/group.  ** 
p < 0.01 
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Figure 4.6:  Stroke decreases rearing in the cylinder task.  A two way repeated measures 
ANOVA showed a significant day by surgery effect (p < 0.0001).  Further investigation of each 
day indicated a significant effect of surgery on day 1 (p = 0.0004) but by day 3 there was no 
effect of surgery or treatment.  Depicted are mean ± SEM for 9 to 10 mice/group. ** p < 0.01; 









































































































































































































Supplemental Table 4.2:   Modified neurological stroke severity score (adapted from Chen 
et al., 2005) 
 
Subtest                 Score 
 
Walking Test          3 
 Normal              0 
 Inability to walk straight            1 
 Circling toward paretic side            2 
 Falling down toward paretic side           3 
 
Beam Balance Test         6 
 Balances steadily or traverses beam to clamp          0 
 Grasps sides of beam ( 60 > x > 50 sec)                1 
 Hugs beam and/or 1 limb slips/falls down ( 50 > x > 40 sec)        2 
 Hugs beam, 2 limbs slip/fall down and/or spins on beam ( 40 > x > 30 sec)       3 
 Attempts to balance but very unsteady (30 > x > 20 sec)          4 
 Attempts to balance but clings to underside of beam (20 > x > 10 sec)          5 
 No attempts to balance and falls ( > 10 sec)           6 
 
Inverted Test          3 
 Forelimb flexion or limb not moving to aid with balance        1 
 Hindlimb flexion or limb not moving to aid with balance        1 
 Head moved more than 10 degrees from vertical center or persistent spin      1 
  
           Total = 12 
 
***NOTE for Beam Balance: an animal that balances steadily but falls due to traversing or 
exploring the beam should still score close to zero. Similarly, an animal that balances poorly but 














































Understanding the role inflammation plays in the etiology and the pathophysiology of stroke is 
critical for advancing the field of stroke research.  Cytokine production and inflammatory cell 
infiltration into the brain post-ischemia has been accepted for years; however, the molecular 
mechanisms underlying this immune response are just now being studied.  Despite substantial 
research and development efforts, there is still only one FDA approved treatment for stroke, tPA.  
Previous work has explored several mechanisms of neuroprotection through ion channels, 
excitatory amino acids, and oxygen radicals, but none have culminated in an effective 
therapeutic effect.  Key findings in the field support that inflammatory cells and mediators such 
as cytokines are important contributing and confounding factors in ischemic brain injury.  
However, our limited understanding of the multi-faceted and complex events of immune 
activation following stroke has resulted in many unsuccessful attempts to translate our 
knowledge of these key inflammatory mediators into therapies for stroke.  Inflammatory 
signaling is involved in the damaging events and the tissue repair stages of the ischemic cascade.  
Many mediators involved in the ischemic cascade have dual roles; thus, it is important to 
understand specific inflammatory mediators that act in spatial and temporal relationships to 
develop effective and novel therapeutic strategies.  My dissertation focused on one pro-
inflammatory cytokine, TNF-α, which is involved in many co-morbid factors, infection, and 
post-stroke inflammation.  Although TNF-α is clearly not the only cytokine involved, it has been 
correlated with stroke in numerous clinical studies and assessed extensively in animal models.  
However, its mechanism of action in neurons at clinically relevant concentrations and exposure 




TNF-α and mitochondrial function  
Our studies show that TNF-α rapidly and profoundly reduces neuronal cell mitochondrial 
function.  It is widely accepted that mitochondria play a role in neuro-inflammation and 
neurodegenerative CNS disorders such as multiple sclerosis, Alzheimer’s disease, and 
Parkinson’s disease (Di Filippo et al., 2010).  With an insult like ischemic stroke, activation of 
microglia occurs that leads to the release of TNF-α along with other pro-inflammatory cytokines 
(Davalos et al., 2005).  Pro-inflammatory cytokines can activate mitochondria-induced apoptosis 
leading to cell death (Huang et al., 2005).  Our findings demonstrate that TNF-α exposure caused 
neuronal mitochondrial dysfunction as expressed by decreased mitochondrial respiration as early 
as 1.5 hours of exposure.   
 
Neurons have a high ATP demand (Zhu et al., 2012), and a temporary reduction in ATP 
production results in a profound decrease in neuronal viability (Simpkins et al., 2010).  Fiskum et 
al. (1999) hypothesized that neuronal death that occurs at the core of an infarct after ischemia 
results from the decrease in mitochondrial and glycolytic ATP production. TNF-α is known to 
exacerbate infarct size in pre-clinical models of stroke, and this may be due to the profound and 
rapid decrease in ATP production, caused by TNF-α release in the evolving ischemic core.  
We hypothesized that TNF-α affects mitochondrial function through TNF-R1 because soluble 
TNF-α signaling is primarily through TNF-R1 (Wajant et al., 2003; Maddahi et al., 2011).  
Blocking TNF-R1 ameliorated the neurotoxic effects of TNF-α on mitochondrial respiration and 
cell viability, confirming TNF-α exerts neurotoxic effects through TNF-R1.  To further 
understand the neurotoxic mechanisms of TNF-α, we assessed caspase 8 and caspase 3/7 activity 
because TNF-α can signal through TNF-R1 and activate caspase 8 or caspase 3/7 (Baud and 
128 
 
Karin, 2001; McCoy and Tansey, 2008).  The activation of caspase 8 causes mitochondrial-
induced apoptosis through the cleavage of Bcl-2-associated X protein (BAX) and BH3 
interacting-domain death agonist (BID) (Aggarwal, 2003; McCoy and Tansey, 2008).  Caspase 8 
activity was increased in a dose-dependent manner after exposure to TNF-α for 1.5 hours; 
however, caspase 3/7 activity was not affected at this early time.  The increase in caspase 8 
activity led us to hypothesize that mitochondrial membrane potential should decrease if caspase 
8 is initiating mitochondrial-induced apoptosis (Green and Kroemer, 2004).  The TMRE 
mitochondrial membrane potential assay showed a significant dose-dependent decrease in 
mitochondrial membrane potential after 1.5 hour of TNF-α exposure.  Furthermore, with a 
collapse of mitochondrial membrane potential there should be an increase in cytochrome c release 
from the mitochondria, due to the cleavage of BAX and BID (Baud and Karin, 2001; Aggarwal, 
2003; McCoy and Tansey, 2008).  After exposure to 100 pg/ml of TNF-α for 3 and 24 hours, 
there was an 11% and 68% increase in cytochrome c release, respectively, from mitochondria.  
Our observation of a 19.7% decrease in mitochondrial membrane potential and the 30% decrease 
in ATP production at 1.5 hours of treatment with 100 pg/ml TNF-α indicates that sufficient 
cytochrome c is released to induce apoptosis (Sas et al., 2007).  Once cytochrome c is released, 
cytochrome c interacts with apoptotic protease-activating factor-1 (Apaf-1), procaspase-9, and 
dATP forming an apoptosome (Sas et al., 2007).  The formation of the apoptosome allows for 
the activation of caspase-9, which activates procaspase-3, and results in the induction of 
apoptosis (Sas et al., 2007).   
 
HT-22 cells and primary mouse cortical neurons both showed a rapid mitochondrial impairment 
and subsequent cell death in response to low concentrations of TNF-α. However, there was a 
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notable difference between the two cell types in the timing of the TNF-α induced cell death. 
Whereas HT-22 cells died within 3 hours of exposure, primary neurons showed cell loss only at 
24 hours. The reason for this delayed response of primary neurons is not clear, but is consistent 
with the comparative resistance of primary neurons to TNF-α in other studies (Reimann-Philipp 
et al., 2001; Zhao et al., 2001). We suspect, but do not have evidence to support, that primary 
neurons may have inherent defense mechanisms that resist the neurotoxic effects of a single 
cytokine, like TNF-α (Tamatani et al., 1999).  
 
Numerous studies reported an association between increased levels of TNF-α mRNA and protein 
and an exacerbation of ischemic injury (Di Filippo et al., 2010).  Administration of TNF-α-
blocking antibodies or soluble TNF-R1 prior to inducing stroke reduces infarct volume 
(Murakami et al., 2005; Di Filippo et al., 2010).  Our findings may provide the mechanism of 
TNF-α exacerbation of stroke damage and shows that TNF-α elicits neurotoxic effects by 
inducing a rapid mitochondrial dysfunction mediated through TNF-R1 signaling subsequently 
activating caspase 8 and leading to the release of cytochrome c.   
 
Current clinical treatment of ischemic stroke concentrates on dissolving and/or removing the 
clot, without much focus on the secondary damage that occurs as part of the inflammatory 
ischemic cascade (Works et al., 2013).  Inflammation is known to play a major role in the 
pathophysiology of stroke and progression of damage post-stroke (Vila et al., 2000a; Iadecola 
and Anrather, 2011).  The identification of a new therapeutic to reduce brain damage due to 
inflammation post-stroke would be clinically useful. However, TNF-α has both pro-apoptotic 
and anti-apoptotic activities, and both roles are important physiologically (Aggarwal, 2003). 
130 
 
When the expression of TNF-α is profound and prolonged, such as after stroke, it has harmful 
effects (Aggarwal, 2003).  Thus, understanding the neurotoxic mechanism of TNF-α is important 
to further advance its potential as a therapeutic target. 
 
As with all in vitro studies, our studies have some limitations, and we interpreted our results with 
caution.  First, TNF-α was administered at discrete doses (1-1000 pg/ml) for 1.5 to 24 hours.  
Post- stroke concentrations change over time and are elevated in patients within 6 hours of 
symptom onset and stay elevated for up to 10 days (Zaremba and Losy, 2001; Intiso et al., 2003).  
Furthermore, TNF-α mRNA is increased in the ischemic core within 1 hour, and TNF-α 
immunoreactive protein is seen within 2-6 hours in the brain after middle cerebral artery 
occlusion, (MCAO) in preclinical models (Liu et al., 1994; Botchkina et al., 1997).  We observed 
mitochondrial impairment with clinically relevant concentrations of TNF-α over a critical time 
window post-stroke.  An additional limitation is the use of cell culture models such as a 
transformed cell line and a primary mouse neuronal culture.  Both cell types are models for 
neurons, but do not have astrocytes, microglia, or endothelial cells; thus, the results should be 
taken with caution.  In view of the similarity between the two models, we believe we have 
modeled the effects of TNF-α on nerve cells.  Finally, we did not evaluate cleavage of BAX and 
BID.  We assumed the cleavage occurred because caspase 8 cleaves BAX and BID, resulting in 
cytochrome c release.   Our results support that exposure to TNF-α at 1.5 hours results in an 
increase in caspase 8 activity, and by 3 hours we observed a significant release of cytochrome c 




The first part of my dissertation shows, for the first time, a rapid and profound mitochondrial 
dysfunction in neurons with acute exposure to low doses of TNF-α.  This neurotoxic effect of 
TNF-α appears to be mediated by TNF-R1, leading to caspase activation, mitochondrial 
membrane potential collapse, and mitochondrial release of cytochrome c.  Collectively these data 
help to elucidate the neurotoxic mechanisms of TNF-α, and thereby, provides potential targets 
for cytokine directed therapy for neuroprotection.   
 
Implications 
Post-ischemic inflammation acts through redundant pathways; thus, blocking TNF-α or any one 
inflammatory mediator will most likely not be effective.  Therapeutic strategies blocking 
multiple inflammatory pathways or neutralizing upstream mediators of the ischemic cascade 
could be more effective.  In experimental models, inhibition of toll like receptors and 
complement is highly protective; however, the potential downside of blocking multiple 
inflammatory pathways or neutralizing complement or toll like receptors is worsening of 
infections after stroke.  30% of patients develop an infection during the acute phase after stroke, 
and pneumonia is an independent risk factor for poor outcome and death.  Thus, targeting 
multiple inflammatory pathways or neutralizing upstream mediators may not be effective 
clinically due to increasing the risk in post-stroke infections.   
 
Indeed the intertwined relationship between the immune system and the CNS is complex and not 
well understood, but understanding the interaction is essential to harness the full therapeutic 
potential of the immunology of stroke.  Studying the neurotoxic signaling pathways of specific 
inflammatory mediators that have a spatial and temporal effect such as TNF-α, will allow the 
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field to develop new therapeutic targets that can target the deleterious effects of the inflammatory 
mediator specifically.  TNF-α has been shown to participated in stroke initiation, progression of 
brain damage acutely post-stroke, tolerance to ischemia, and repair and recovery after stroke as a 
mediator and modulator of inflammation.  Thus, neutralizing TNF-α with Etanercept or 
infliximab, FDA approved anti-TNF therapies, will most likely not be clinically effective 
because 1) low blood-brain barrier permeability of the drugs and 2) its role of control and 
resolution of inflammation opposing its potent cytotoxicity.  Targeting the cytotoxic effect of 
TNF-α acutely after ischemia will potentially provide neuroprotection through limiting ischemic 
damage while still allowing TNF-α to be a mediator in the repair phase post-stroke.  Since we 
have shown that TNF-α affects neuronal mitochondrial function, a possible therapeutic 
intervention could be increasing mitochondrial function or targeting caspase 8 downstream of 
TNF-α signaling to prevent neuronal cell death and limit brain damage.   
 
Moreover atherosclerosis, diabetes, obesity, and infection cause inflammation that contributes to 
vascular injury and increases the risk of stroke.  TNF-α is an essential cytokine in all of these co-
morbid factors.  Stroke is most commonly caused when an atherosclerotic plaque ruptures, and in 
particular, TNF-α plays a key role in not only the development of atherosclerotic plaques but 
their destabilization.  When monocytes and macrophages were primed and activated to express 
high levels of TNF-α when stimulated, rats with no risk factors for stroke were sensitive to 
induction of brain ischemia by intraventricular administration of LPS (28).  Administration of 
recombinant type I soluble TNF receptor prevented these strokes implicating TNF-α as a 
necessary causal factor (28).  Conventionally, prevention of cerebrovascular disease involve 
inhibition of platelet aggregation and the coagulation cascade; however, measures to control the 
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TNF-α signaling pathway involved in increasing susceptibility stroke could be used as a 
preventive therapeutic. 
 
In support of using TNF-α antagonists or targeting the TNF signaling pathway as a possible 
preventive therapeutic for individuals with increased risk for stroke, rheumatic disorders such as 
rheumatoid arthritis are characterized with chronic and progressive inflammation similar to many 
co-morbid stroke risk factors.  TNF-α is a key cytokine in rheumatic disorders, and various TNF-
α antagonists are used for treatment.  A Danish study with 18,247 rheumatoid arthritis patients, 
followed for a median of 4.8 years, reported a 30% higher risk of ischemic stroke compared to 
those without rheumatoid arthritis (Lindharsen et al., 2012).  While traditional stroke risk factors 
are more prevalent in patients with rheumatoid arthritis, these factors do not fully explain the 
enhanced cerebrovascular risk in this population.  Current research in this field suggests that 
systemic inflammation is a key player, and rheumatoid arthritis patients taking TNF-α 
antagonists had a lower risk for ischemic stroke (Naranjo et al., 2008).  However, no randomized 
study has corroborated this trend.   
 
TNF-α participates in every facet of stroke: the etiology, pathophysiology, and recovery and 
repair phase.  The current knowledge of TNF signaling has been studied extensively in non-
neuronal cells, and the few studies in neurons use high concentrations and long periods of 
exposure.  Thus, future studies need to focus on the cooperative role for TNF-α in the complex 
ischemic cascade that regulates neuronal life/death decisions and the response of brain cells to 
ischemic injury.  This improved understanding of TNF mechanism in stroke will improve stroke 
treatment and prevention.   
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Infection and mitochondrial function  
Recent studies have indicated that both Helicobacter pylori (H. pylori) (Wang et al., 2012) and 
human cytomegalovirus (HCMV) (Huang et al., 2012) infections are associated with increased 
risk for ischemic stroke.   Moreover, having a respiratory tract infection increases the risk for an 
atherothrombotic ischemic event for up to 3 months (Zurru et al., 2009) and chronic bronchitis 
increases risk for stroke and transient ischemic attacks (TIA) (Grau et al., 2009).   Lastly, 
Grabska et al. (2011) conducted a retrospective chart review of 2066 ischemic stroke patients to 
assess the effect of pre-stroke and post-stroke infection on ischemic stroke severity and found 
that pre-stroke infection increased poor outcomes within the first 30 days but did not have effects 
at 90 days on modified Rankin scores.  Although much is known about the factors that worsen 
stroke severity in clinical subjects and experimental stroke models, less is understood about their 
mechanisms.  
 
The blood-brain barrier (BBB) is a highly specialized vascular interface that maintains 
homeostasis in brain by separating the blood compartment from the central nervous system 
(CNS). Disruption of cerebrovascular endothelial cells not only allows entry of unwanted solutes 
into brain, but also disrupts the normal CNS entry route of critical nutrients.(Rubin and Staddon, 
1999; Gonzalez-Mariscal et al., 2000) The BBB excludes the majority of bacteria; however, 
similar to ischemia and reperfusion, inflammation induced by bacteria alters BBB permeability. 
Thus far, studies have provided evidence that the release of oxidants, proteolytic enzymes and 
inflammatory cytokines alter BBB permeability.  Previous studies found that an LPS challenge 
results in a larger infarct volume (McColl et al., 2007), impairs survival and disrupts BBB 
(Denes et al., 2011) in experimental stroke models, through mechanisms that are proposed to 
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involve cytokines.  As noted, TNF-α is increased during infections along with other co-morbid 
factors that increase risk for stroke, and because we found that TNF-α rapidly and profoundly 
decreases mitochondrial function, we hypothesized that the LPS exacerbation of infarct volume 
is due decreased endothelial mitochondrial function resulting in increased BBB permeability.   
Our data are the first to demonstrate that a bacterial infection mimic acts with ischemic challenge 
to markedly exacerbate stroke damage via a mitochondrial-dependent mechanism. This new 
finding could also provide an explanation for the association of infections with severity of brain 
damage and BBB dysfunction from stroke: the induction of hypometabolism in cerebrovascular 
endothelial cell mitochondria.  
 
Mitochondrial dysfunction is increasingly recognized as an accomplice in vascular diseases and 
ischemic stroke. More recently, it has been shown that components of the TLR4 signaling 
pathways, MyD88 and TRAF6, are linked with mitochondria and affect oxidative 
phosphorylation.(Kim et al., 2007). The expression of MyD88 in mitochondria of endothelial 
cells supports that mitochondrial function can be affected by LPS. It is notable that we observed 
no significant effect of LPS is seen on cCVEC basal oxygen consumption and ATP-linked 
oxygen consumption upon treatment with oligomycin, indicating that LPS does not significantly 
change basal oxygen demand in mitochondria after 24 hours of treatment. However, the loss of 
maximal respiration and spare capacity demonstrates that mitochondrial capacity is reduced by 
LPS and thus the effects exacerbate the mitochondrial impairment by ischemia.  Cellular 
respiration, mitochondrial biogenesis and function, require coordinated expression of proteins 
encoded by nuclear and mitochondrial genes including mitochondrial complex I-IV. The reduced 
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expression of respiratory chain complex I, III and IV proteins in cCVECs by LPS provides 
further evidence that LPS compromises the endothelial mitochondria function. 
 
The 30 minute tMCAO model mimics a mild ischemic event that results in a small infarct and 
does not cause visible BBB disruption at 6 hours reperfusion.  The bacterial infection mimic 
challenge prior to tMCAO increased BBB permeability and exacerbated infarct volume. There 
are inconsistent data for LPS- or cytokine-induced BBB dysfunction (Banks and Erickson, 2010) 
that may be due to complex mechanisms.  McColl et al.(2007) demonstrated an interleukin-1-
dependent mechanism of stroke exacerbation using the same LPS-tMCAO model.  Others have 
demonstrated that LPS alters transporters or enzymes involved in BBB maintenance (Banks et 
al., 2008). Our observation that pharmacological inhibition of mitochondria disrupts BBB 
integrity and increases BBB permeability in vitro and in vivo strengthens the argument that BBB 
permeability is increased by LPS after stroke through a direct mitochondrial mechanism resulting 
in a larger infarct volume and worsening neurological deficit.  
 
Increased BBB permeability, is positively correlated with massive vasogenic and cytotoxic 
edema post-stroke (Taheri et al., 2009; Yang and Rosenberg, 2011) and elevated neutrophils in 
the ischemic area that contribute to infarct expansion (Bektas et al., 2010) and poor clinical 
outcome (Warach and Latour, 2004). Our observation of neutropenia and low NLR may be a 
consequence of BBB damage that causes rapid migration of neutrophils into damaged tissue. 
Brain infiltration of neutrophils could also account for secondary lesion growth and increased 
infarct size in the ischemic brain as seen with LPS treatment.  These data may provide 
translational evidence that neutropenia and low NLR may predict severe stroke.  
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We observed that LPS-induced inhibition of mitochondria exacerbates infarct volume and opens 
BBB in tMCAO mice, but that mitochondria inhibition in cCVECs and pCVECs does not affect 
cell viability in 24 hours. This suggests that the functional impairment of endothelial 
mitochondria by LPS may be reversible and an effective intervention could be designed to 
prevent/restore BBB during strokes. However, our data also indicated that a high dose of LPS 
(100 μg/ml) induced cell death and reduced cell viability in cCVECs, and extension of LPS 
exposure for 48 hours induced cell death in both cCVECs and pCVECs. Therefore, the effective 
mitochondrial directed intervention may be limited by the severity or the length of the infectious 
exposure to rescue BBB damage.  
 
Leukocytosis, and cytokine and chemokine storm are features of the acute-phase reaction in 
systemic infections and in acute stroke. It is becoming increasingly apparent that inflammation 
can disturb cell energy metabolism.  Our recent study found that neuronal mitochondrial function 
was rapidly and profoundly decreased by TNF-α resulting in neuronal cell death (Doll et al., 
2015a). Another study demonstrated that TNF-α elevated oxygen consumption rate in 
endothelial cells (Drabarek et al., 2012). The present study did not address the complex LPS-
induced effects on mitochondria, however, our novel findings refreshed the traditional idea of 
infection-inflammation responses and provided a new explanation for the LPS effects on BBB 
dysfunction: a direct mitochondrial-dependent mechanism. 
 
The application of rotenone on the epidural surface argues that its effect on BBB opening is by 
compromised mitochondria in vascular endothelial cells. Rotenone exposure is associated with 
clinical features of parkinsonism in humans (Tanner et al., 2011), and broadly used to induce PD 
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like-symptoms in animal models (Chesselet and Richter, 2011) as well. This suggests that the 
mitochondrial-dependent BBB opening may not only involve in the progress of stroke but also 
other neurodegenerative disorders such as PD and AD. 
 
In summary, the second part of my dissertation describes a previously unknown mechanism of 
infection-induced direct mitochondrial dysfunction in cerebrovascular endothelial cells, which 
compromises BBB permeability and exacerbates acute stroke outcomes. Moreover, our 
observations argue that maintenance of mitochondrial function is critical to the integrity of the 
BBB. The data also suggest a translational significance: maintenance of brain endothelial cell 
mitochondrial function can improve the acute outcome of stroke and perhaps other 
neurodegenerative diseases.  
 
Statistical Limitation 
As with all studies there are limitations such as sample size.  When a sample size is small, some 
have cautioned against using the t-test.  However, De Winter (2010) provided full analysis of 
using the Student’s t-test with a small sample size.  De Winter (2010) reported that the t-test 
provides Type I error rates close to the 5% nominal value in most of the cases (n = 2 ~ 5) and 
that acceptable power (80%) is reached only if the effect size is very large.  Moreover, William 
Sealy Gosset developed the t-test for small sample sizes (Lehmann, 2012).  Gosset verified his t-
distribution on anthropometric data of 3,000 criminals which he divided into 750 samples each 
having an n = 4.  It was concluded that there are no principle objections to using a t-test with Ns 
as small as 2.  We had an n = 3 for each group which was replicated 3 times for the experiment 
139 
 
testing the effects of LPS on brain endothelial cell mitochondrial function, and we had an n = 3 
for the experiment testing the effects of pharmacological inhibition of mitochondria on BBB 
permeability.  Both of these studies are in vitro studies which by nature are highly homogeneous 
resulting in low variances among groups unlike animal and human studies.  Thus, a small sample 
size is acceptable and routinely used in the field.    
 
Implications 
Increased cytokine expression is found centrally and peripherally after ischemic stroke; however, 
the evidence for central expression of cytokines has predominately come from experimental 
stroke models and for peripheral expression has come from human studies.  Thus, this method of 
studying cytokines in stroke results in a huge gap in knowledge.  Moreover, experimental stroke 
studies are invasive and could contribute to the cytokine response confounding our 
understanding of the spatial and temporal response of these cytokines.  As noted early, TNF-α 
has polyphasic roles during ischemia as well as many other of the cytokines.  In experimental 
stroke studies, TNF-α has been shown to induce preconditioning, increase susceptibility, and be 
neuroprotective.  Since chronic over expression or chronic deprivation, via receptor knockout, is 
not what is endogenously normal, other studies have acutely inhibited TNF-α and showed 
neuroprotection.  Thus, the next phase of research needs to be the assessment of the roles of 
these complex cytokines during stroke to understand the upstream pathways that regulate the 
expression of these cytokine and the downstream pathways that amplify inflammation.   
There is a general consensus in the field that blocking a single cytokine or inflammatory 
mediator will not be an effective therapeutic intervention.  Thus, discovering that TNF-α affects 
mitochondrial function and that infection prior to ischemia increases BBB permeability through a 
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mitochondrial-dependent mechanism suggests that targeting mitochondria could improve stroke 
outcome.   
 
Mitochondria are the powerhouses of the cells and involved with oxidative phosphorylation, 
calcium homeostasis, reactive oxygen species (ROS) management, and programmed cell death 
(Vosler et al., 2009).  Disturbing the mitochondrial membrane potential results in caspase- 
dependent and -independent forms of cell death (Taylor et al., 2008; Galluzzi et al., 2009).  In 
caspase-dependent cell death, cytochrome c release activates the caspase cascade causing 
cleavage of numerous proteins and DNA damage (Taylor et al., 2008).  In caspase-independent 
cell death, calpain - or poly (ADP-ribose) polymerase-1 (PARP1)-mediated apoptosis inducing 
factor (AIF) is released from the mitochondria and translocates to the nucleus (Galluzzi et al. 
2009).  Studies inhibiting these downstream mitochondrial death effectors through inhibition of 
caspases, overexpression of X-lined inhibitor of apoptosis (endogenous caspase inhibitor), 
HSP70 (binds and sequesters AIF released from the mitochondria), and AIF deletion have shown 
neuroprotection acutely post-ischemia (24 hours – 1 week) (Galluzzi et al., 2009; Galluzzi et al., 
2010).  Thus, targeting downstream effectors has only short-term protection which is likely due 
to the presence of compensatory mechanisms of the mitochondria or to mitochondria-
independent mechanisms like increased oxidative stress.   
 
Since targeting downstream effectors appear to only have short-term protection and the damage 
done may be too extensive to reverse, targeting direct effectors of mitochondrial membrane 
disruption may be more advantageous.  The Bcl-2 family of pro-death proteins (Bax, Bid, Bad, 
Bim, and PUMA, among others) are involved with mitochondrial impairment (Youle and 
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Strasser, 2008).  Bax directly causes mitochondrial membrane disruption through formation of 
channels in the outer mitochondrial membrane (Youle and Strasser, 2008).  Bid and PUMA aid 
Bax channel formation (Youle and Strasser, 2008).  While, Bad and Bim inhibit pro-survival 
Bcl-2 proteins and Bcl-xL (Youle and Strasser, 2008).  Previous work inhibiting pro-death Bcl-2 
proteins or increasing pro-survival Bcl-2 proteins has shown neuroprotection (Yin et al., 2006; 
Steckley et al., 2007).  A single gene deletion of Bax, Bid, Bim, or PUMA only provided limited 
neuroprotection, but a triple knockout mouse with deletions of Bax, Bid, and PUMA showed a 
prolonged neuroprotection up to 14 days post-ischemia (Vosler et al., 2009).  It appears there is a 
functional redundancy in pro-death Bcl-2 proteins similar to inflammatory signaling pathways; 
thus, targeting a single pro-death Bcl-2 protein similar to targeting one cytokine is not sufficient.  
Thus, a potential target that may provide a more robust neuroprotection would be to target 
natural inhibitors of the pro-death Bcl-2 proteins, pro-survival Bcl-2 proteins or Bcl-xL.   
 
A more attractive target would be to target further upstream to exert more neuroprotection.  MAP 
kinase c-Jun N-terminal kinase (JNK) is consistently activated after cerebral-ischemia (Johnson 
and Nakamura, 2007).  JNK signaling induces programmed cell death in numerous ways; thus, it 
has high therapeutic potential.  JNK activation directly and indirectly regulates pro-death Bcl-2 
family proteins to disrupt mitochondrial membrane potential.  JNK phosphorylates the 
scaffolding protein that causes release and translocation of Bax to mitochondria, and JNK 
phosphorylates Bad and Bim that further activates Bax which inhibits pro-survival Bcl-xL and 
Bcl-2 proteins (Gao et al., 2005).  In addition, JNK signaling alters the transcription of the 
transcription factor c-Jun which promotes up regulation of Fas, Bim, and TNF-α (Mehta et al., 
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2007).  Thus, JNK can induce neuronal death through mitochondrial death pathways and by 
alteration in the genomic response to shift gene expression toward more pre-death mediators.   
It is important to note that JNK is elevated between 0.5 and 24 hours following tMCAO in rats; 
thus, clinically targeting JNK would not be limited to a brief time period post-ischemia to exert 
its neuroprotective roles (Wang et al., 2007b).  Inhibiting JNK using intracerebroventricular 
injection of a pharmacological inhibitor SP600125 or a small peptide inhibitor D-JNKI-1 60 or 
30 minutes post ischemia, respectively, provides robust neuroprotection (Borsello et al., 2003; 
Gao et al., 2005).  Moreover, D-JNKI-1 has been administered 6 hours after ischemia and 
provided long-lasting neuroprotection and neurobehavioral recovery up to 14 days post-ischemia 
(Esneault et al., 2008).  In light of this compelling evidence, targeting JNK signaling is an 
excellent prospect for clinical neuroprotection.   
 
Lastly, mitochondria are important for cellular homeostasis.  Oxidative stress causes extensive 
mitochondrial fission which results in neuron death.  When the mitochondrial fusion protein 
mitofusion 2 is overexpressed, neuronal death can be prevented (Jahani-Asl et al., 2007).  This 
suggests that tight regulation of fission and fusion is important for neuronal viability.  Moreover, 
hypoxia increases mitochondrial DNA, total mitochondrial number, expression of mitochondrial 
transcription factors, and the mitochondrial protein HSP60 which suggests mitochondrial 
biogenesis is an endogenous neuroprotective response (Diaz and Moraes, 2008).  After an 
ischemic insult mitochondria are damaged and autophagy is induced to remove the damaged 
mitochondria.  However, neuronal function is dependent on maintenance of energy levels and 
cellular homeostasis.  Thus, stimulation or enhancement of mitochondrial biogenesis is a novel 
therapeutic strategy.  More research is needed to understand mitochondrial biogenesis in relation 
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to stroke, and future research could focus on the role of alternate transcriptional mechanisms, 
mitochondrial fission and fusion mechanisms, and mitochondrial turnover after ischemia to 
design new therapeutic targets.   
 
Infection and Post-stroke Outcome 
From a preclinical perspective, LPS has been shown to increase infarct volume when 
administered prior to MCAO in rodents (McColl et al., 2007; Doll et al., 2015c).  However, the 
long-term effects of stroke during an active infection have not been studied previously.  The last 
part of my dissertation shows for the first time that low dose LPS increases and prolongs 
sickness behavior and worsens neurological deficits post-stroke.    Thus, infection appears to 
both trigger and worsen severity of stroke. 
 
It is known that a severe stroke results in motor, cognitive, and affective behavioral deficits 
(Markgraf et al., 1994; Rogers et al., 1997; Gibson and Murphy, 2004; Winter et al., 2005; Bouet 
et al., 2007). Further, studies have shown that high doses of LPS causes motor, cognitive, and 
affective deficits (Dunn and Swiergiel, 2005; De Domenico et al., 2010; Hritcu et al., 2011; 
Painsipp et al., 2011; Tarr et al., 2011; Biesmans et al., 2013).  However, until the current study, 
the long-term functional outcomes of stroke in combination with an active infection had not been 
methodically assessed in the rodent model. We hypothesized that the LPS administered prior to 
stroke would exacerbate the motor, cognitive, and affective behavioral deficits post-stroke.  Our 
most robust effects of low dose LPS + mild stroke were on lesion volume, mNSS and sickness. 
The hypothermic response to LPS + stroke could be an adaptive protective response, because in 
other studies, we observed that maintenance of core body temperature following LPS + stroke 
144 
 
resulted in profound sickness and death of mice (Doll et al., unpublished observations) and that 
acute post-stroke hypothermia is strongly associated with larger infarct size in mice (Heng et al., 
unpublished observations). The LPS + stroke effects on mNSS and sickness peaked at one day 
after stroke, then recovered over the 7-day observation period, indicating that acute behavioral 
response to LPS + stroke is transient, as has been previously reported for stroke alone in rodents 
and humans (Schaar et al., 2010; Grabska et al., 2011).  We also showed that stroke, but not LPS 
treatment, affects balance and motor coordination during the accelerating rotarod task. As well, 
we did not observe effects of stroke, LPS, or their combination on open field, elevated plus maze 
or forced swim. Taken together, we demonstrate for the first time that an infection, present at the 
time of brain trauma (induced by MCAO) can exacerbate detrimental stroke outcomes, 
negatively impacting health and significantly prolonging recovery. 
 
Limitations of the present study are several. We did not observe some of the previously reported 
behavioral deficits that have been found following MCAO or LPS among rodents. This is most 
likely due to methodological differences between our work and previous studies including 1) the 
timing of post-manipulation assessments, 2) the severity of the model of brain insult used here, 
and 3) the low dose of LPS used in our study.  Indeed, it is well recognized that there are critical 
periods for detecting post-stroke deficits (Schaar et al., 2010). As well, many studies assessing 
functional outcomes following LPS assessed performance within hours of treatment 
administration. Thus, we may have not seen LPS + stroke effects in some behaviors due to the 
timing of assessment.  Also, severity of the stroke insult may have influenced our ability to 
detect functional deficits.   Our stroke was a 30 minute tMCAO, which is considered a minor 
insult, and caused a small infarct. The low dose of LPS used here, and thus the severity of the 
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infection induced at the time of stroke also may explain why we did not observe substantial 
detrimental behavioral changes. Although others have shown that LPS results in motor, 
cognitive, and affective behavioral deficits, the doses used ranged from 0.3 – 10 mg/kg which are 
3 – 100 times higher than the dose used in the present study.  Additionally, a few studies injected 
LPS multiple times before assessing behavior (Hritcu et al., 2011); thus, the single, low LPS 
dose given in this study likely resulted in a minor bacterial infection mimic, and the chosen 
battery of functional assessments may have not been sensitive enough to detect a mild 
impairment at the time points at which they were administered.  Future studies should assess 
different doses of LPS and determine the time to assess different behavioral deficits.  
Furthermore, an increase prevalence of strokes occurs during flu season. Here, we utilized LPS, a 
bacterial infection mimic. However, it is not clear whether the exacerbation of post-stroke 
functional deficits by LPS found here extend to other types of infection. Thus, the assessment of 
the effects of a viral infection mimic prior to stroke on functional outcome is needed.   
This study was not designed to assess the mechanism(s) of the interaction between LPS and 
stroke, but rather to describe the consequences of this interaction on lesion volume, neurological 
deficits, sickness and behavioral outcomes. There are several potential mechanisms by which 
LPS could exacerbate stroke outcome. LPS itself is neurotoxic (Lehnardt et al., 2003), and 
increases levels of several neurotoxic cytokines, including TNFα (McColl et al., 2007). We have 
shown that TNFα causes neuronal loss by inhibition of mitochondrial oxidative phosphorylation 
(Doll et al., 2015a). Additionally, LPS compromised the blood-brain barrier (BBB) (Doll et al., 
2015c). As such, through either or both mechanisms, treatment with low doses of LPS may 
sensitize animals to the subsequent effects of a mild stroke and thereby worsen outcomes.  
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Thus, we can conclude from this study that a minor bacterial infection mimic prior to a minor 
stroke results in increased infarct area, increased sickness behavior and worse neurological 
deficits resulting in delayed functional recovery.  Our observations of the association between 
infection, stroke, and worse sickness and neurological outcomes argues for the need to 
aggressively treat infection in people with risk factors for stroke and the need to understand the 
mechanism(s) of this association. 
 
Statistical Interpretation  
To simultaneously assess the effects of a minor bacterial infection mimic (LPS) and stroke, we 
designed a two x two factorial ANOVA with treatment (LPS or saline) and surgery (tMCAO or 
sham) as our independent variables.  We performed a two-way repeated measures ANOVA to 
assess the effects of stroke and LPS on sickness behavior and neurological deficits.  Factorial 
designs such as the one implemented here are extremely powerful tools with which   “to assess 
the generality of a finding by studying the effects of one independent variable under different 
conditions, and we evaluate this generality by examining the results of a factorial experiment for 
an interaction between the factors”… “An interaction is present when the effects of one 
independent variable on behavior change at the different levels of the second independent 
variable” (Keppel and Wickens, 194, 201).  For sickness behavior, we had a significant Day x 
Treatment (p = 0.0006) and Day x Surgery (p < 0.0001) interaction.  Thus, we blocked our data 
by days 1 – 3 (acute phase post-stroke) and days 4 – 6 (subacute phase post-stroke) to assess the 
simple main effects of treatment or surgery in the absence of a significant interaction between 
these two independent variables.  During the acute phase post-stroke, there was a significant 
Treatment effect (p = 0.0005) and Surgery effect (p < 0.0001).  However, there was no 
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significant Treatment x Surgery interaction (p = 0.3895).  This indicates that ignoring whether or 
not animals had LPS or saline, animals that underwent tMCAO had increased sickness behavior 
as compared to sham animals.  Similarly, animals who received LPS had increased sickness 
behavior than saline treated animals regardless of surgical status.  During the subacute phase, the 
Surgery effect remained (p < 0.0001), but there was no significant Treatment effect (p = 0.0842).  
We interpreted this data as stroke and LPS affect sickness behavior during the acute phase post-
stroke, but LPS does not exacerbate the effect of surgery on sickness behavior (no Surgery x 
Treatment interaction).  For neurological deficit, we had a significant Day x Treatment (p = 
0.0067) and Day x Surgery (p < 0.0001) interaction.  Thus, we blocked the data similar to 
sickness behavior to further probe this interaction.  During the acute phase (days 1 – 3), there 
was an overall Treatment x Surgery interaction (p = 0.0454) indicating that the effect of LPS 
treatment among stroke animals was larger in magnitude than the effect of LPS treatment among 
sham animals.  Thus, the effect of stroke on neurological deficit was exacerbated by LPS 
treatment present at the time of brain injury.  During the subacute phase (days 4 – 6), the 
Treatment x Surgery interaction was not observed (p = 0.7531), but a main effect of surgery was 
observed (p < 0.005).  By days 4 – 6, the neurological deficit observed was due to surgery alone.  
LPS did not further exacerbate this deficit (p = 0.7531).   
 
Implications 
In at least a third of ischemic stroke cases, the patients lack traditional risk factors and have no 
apparent cause.  These findings and the observation that thirty to forty percent of strokes occurs 
during or acutely after an infection (Grau et al., 1995b) suggest an association between systemic 
infection and stroke.  Although infection has been implicated in increasing susceptibility to 
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stroke, few studies have examined how an infection prior to stroke affects post-stroke outcome.  
Thus, our findings suggest that an infection prior to stroke increases sickness behavior and 
worsens neurological deficits resulting in a delayed functional recovery.  These findings should 
warrant change in clinical practice.   
 
Currently, individuals with infections are prescribed antibiotics and advised to get rest and drink 
fluids.  As long as there are no complications, these patients rarely have a follow-up doctor 
appointments.  Since infection is a risk factor for stroke, populations of individuals that have 
other co-morbid stroke risk factors or are at a higher risk for stroke should be monitored by their 
family doctors closely during an active infection.  Follow-up visits and education about their 
increased risk for stroke should be implemented into clinical practice to help prevent stroke.  
Although stroke is the leading cause of disability in the United States and is a huge financial 
burden, it can be prevented.  Thus, clinical practice changes and education are two strategies in 
preventing a first stroke which is a major goal of the National Stroke Association.   
 
In addition to infection and other co-morbid factors increasing risk for stroke, after having a 
stroke or a transient ischemic attack (TIA), the risk of stroke within 3 months is between 15 – 
20% (Wu et al., 2007).  Post-stroke, patients have immune suppression.  It is thought that this 
immune depression is an adaptive response to help prevent autoimmunity against CNS antigens 
because studies have correlated the amount of infarcted brain tissue with the concentrations of 
CNS antigens (Jauch et al., 2006).  Moreover, a Th1 response against these CNS antigens has 
been associated with poor 3-month functional outcome (Becker et al., 2011).  However, it is 
unclear whether this stroke-related autoimmunity to brain antigens is a consequence or a causal 
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for post-stroke immune suppression.  Another mechanism could be over activation of the 
adrenergic system releasing catecholamines and corticosteroids which is supported by increased 
serum cortisol and catecholamine levels in patients, and the elevated cortisol levels are an 
independent predictor of mortality (Anne et al., 2007).  Other studies have shown that depletion 
of noradrenergic terminals in the liver or β-adrenergic blockade of these receptors alters cytokine 
expression by hepatic invariant Natural Killer cells (iNKT) resulting in decreased immune 
suppression, bacterial infections, and decreased mortality in experimental stroke models 
suggesting adrenergic nerve terminals in peripheral organs mediate the adrenergic post-stroke 
immune suppression (Wong et al., 2011).  Although it is unclear the mechanism by which 
immune suppression occurs post-stroke, it is known to lead to an increased incidence of 
infections post-stroke (Famakin, 2014).  Recent studies have shown that up to 30% of stroke 
patients have pneumonia or urinary tract infection acutely after stroke, and infections are the 
leading cause of death in stroke patients (Westendorp et al., 2011).  This increased risk of 
infection post-stroke is concerning not only because of its negative impact on outcomes, but the 
increased risk of infection could lead to 1) increased susceptibility to a second stroke and 2) 
worsen the neurological outcome of a second stroke. 
 
Currently, clinical trials have treated stroke patients prophylactically with antibiotics to prevent 
post-stroke infections.  The ESPIAS trial had no effect on infection rate or on mortality 
(Chamorro et al., 2005).  However, the PANTHERIS trial found that infection rate was 
decreased but the mortality rate was not significantly affected.  The lack of effect on mortality 
rate may be due to that the antibiotic treatments are not targeting the endogenous mechanisms 
proposed above, autoimmunity to CNS antigens or adrenergic suppression.  Moreover, 
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prophylactically administering antibiotics pre-stroke in high risk patients or post-stroke could 
result in a worse immune suppression complicating post-stroke outcomes further.   
 
Preconditioning in the stroke field is an attractive preventive method for stroke.  Preconditioning 
is when a sublethal injurious stimulus protects an organ against a subsequent lethal stimulus 
(Iadecola and Anrather, 2011).  Preconditioning with low doses of LPS, transient non-damaging 
ischemic insult to the brain, and administration of recombinant T cell receptor ligand (suppresses 
the infiltration of inflammatory cells) provides neuroprotection and protects the brain from 
ischemic damage (Subramanian et al., 2009; Bune et al., 2010; Moskowitz et al., 2010; Jensen et 
al., 2011).  Preconditioning studies have shown that a balance of anti- and pro-inflammatory 
mediators is required for the protection because simply suppressing the production of pro-
inflammatory cytokines or the infiltration of inflammatory cells is not effective (Ohtsuki et al., 
1996; Blondeau et al., 2001; Pradillo et al., 2005; Kunz et al., 2007).  Thus, prophylactically 
treating individuals with antibiotics that are at a high risk for stroke is most likely not a 
beneficial preventive method.  However, immune modulation pre- and post-stroke has significant 
potential.  Further understanding of the immunology of stroke is needed and will enable the 
development of targeted approaches to selectively suppress the deleterious effects of 
inflammation.   
 
Conclusions 
My dissertation has provided the field of stroke with the knowledge that TNF-α rapidly and 
profoundly decreases mitochondrial function resulting in neuronal cell death and endothelial cell 
mitochondrial dysfunction is linked to LPS-induced increased BBB permeability.  Moreover, this 
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increased BBB permeability by a bacterial infection mimic results in increased ischemic brain 
damage and delayed functional recovery post-stroke.  My research along with others studying 
mechanistically how the immune system and the ischemic brain interacts is essential to guide 
therapeutic interventions.  Outlined above are various potential therapeutic interventions for 
ischemic stroke.  I believe that more research should focus on the role of mitochondrial 
biogenesis in neurons because stimulation or enhancement of mitochondria is a novel 
neuroprotective strategy.  Since we show that not only TNF-α exerts its neurotoxicity through 
mitochondrial dysfunction but BBB permeability is mediated through mitochondrial dysfunction, 
maintenance of mitochondrial biogenesis or targeting mediators of autophagy to enhance the 
beneficial effects of mitochondrial preservation may provide neuroprotection at all stages pre and 
post-ischemia.  The current research suggesting the remarkable impact of modulating the 
immune system has on stroke damage and recovery justifies the field’s need to aggressively 
pursue basic and clinical studies to elucidate the interaction between the immune and nervous 
system pre- and post-stroke.  In the near future, tPA will not be the only treatment for stroke.  
Strategies to enhance mitochondrial function will be utilized in addition to tPA to improve acute 

























































































































Figure A1: IL-1 alpha, IL-1beta, IL-2, and IL-4 levels 30 minutes after no (naïve), 100 μg/kg 







































































































 Figure A2: IL-6, IL-10, IL-12, and IL-17 alpha levels 30 minutes after no (naïve), 100 μg/kg 











































































































 Figure A3: IFN-gamma, TNF-alpha, G-CSF, and GM-CSF levels 30 minutes after no (naïve), 
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